<!DOCTYPE html>
<html lang="en" dir="ltr" class="client-nojs">
<head>
<meta charset="UTF-8" />
<title>Myelodysplastic syndrome - Wikipedia, the free encyclopedia</title>
<meta name="generator" content="MediaWiki 1.26wmf13" />
<link rel="alternate" href="android-app://org.wikipedia/http/en.m.wikipedia.org/wiki/Myelodysplastic_syndrome" />
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit" />
<link rel="edit" title="Edit this page" href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit" />
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png" />
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico" />
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd" />
<link rel="alternate" hreflang="x-default" href="/wiki/Myelodysplastic_syndrome" />
<link rel="copyright" href="//creativecommons.org/licenses/by-sa/3.0/" />
<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
<link rel="canonical" href="https://en.wikipedia.org/wiki/Myelodysplastic_syndrome" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.uls.nojs%7Cext.visualEditor.viewPageTarget.noscript%7Cext.wikihiero%7Cmediawiki.legacy.commonPrint%2Cshared%7Cmediawiki.sectionAnchor%7Cmediawiki.skinning.interface%7Cmediawiki.ui.button%7Cskins.vector.styles%7Cwikibase.client.init&amp;only=styles&amp;skin=vector&amp;*" />
<meta name="ResourceLoaderDynamicStyles" content="" />
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=site&amp;only=styles&amp;skin=vector&amp;*" />
<style>a:lang(ar),a:lang(kk-arab),a:lang(mzn),a:lang(ps),a:lang(ur){text-decoration:none}
/* cache key: global:resourceloader:filter:minify-css:7:de1ab5287c9076b96eedd3f97a84a7b6 */</style>
<script src="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=startup&amp;only=scripts&amp;skin=vector&amp;*"></script>
<script>if(window.mw){
mw.config.set({"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":false,"wgNamespaceNumber":0,"wgPageName":"Myelodysplastic_syndrome","wgTitle":"Myelodysplastic syndrome","wgCurRevisionId":669828767,"wgRevisionId":669828767,"wgArticleId":186367,"wgIsArticle":true,"wgIsRedirect":false,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["CS1 maint: Explicit use of et al.","Articles with contributors link","All articles with unsourced statements","Articles with unsourced statements from April 2011","Commons category with local link same as on Wikidata","Articles that use a Medicine navs subtemplate","Wikipedia articles with GND identifiers","Myeloid neoplasia","Syndromes"],"wgBreakFrames":false,"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgMonthNamesShort":["","Jan","Feb","Mar","Apr","May","Jun","Jul","Aug","Sep","Oct","Nov","Dec"],"wgRelevantPageName":"Myelodysplastic_syndrome","wgRelevantArticleId":186367,"wgIsProbablyEditable":true,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgRedirectedFrom":"Myelodysplastic_syndromes","wgMediaViewerOnClick":true,"wgMediaViewerEnabledByDefault":true,"wikilove-recipient":"","wikilove-anon":0,"wgPoweredByHHVM":true,"wgWikiEditorEnabledModules":{"toolbar":true,"dialogs":true,"hidesig":true,"preview":false,"publish":false},"wgBetaFeaturesFeatures":[],"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","usePageImages":true,"usePageDescriptions":true},"wgGatherShouldShowTutorial":true,"wgGatherPageImageThumbnail":"//upload.wikimedia.org/wikipedia/commons/thumb/8/89/Tumor_Myelodysplastic_Spleen.JPG/100px-Tumor_Myelodysplastic_Spleen.JPG","wgULSAcceptLanguageList":[],"wgULSCurrentAutonym":"English","wgFlaggedRevsParams":{"tags":{"status":{"levels":1,"quality":2,"pristine":3}}},"wgStableRevisionId":null,"wgCategoryTreePageCategoryOptions":"{\"mode\":0,\"hideprefix\":20,\"showcount\":true,\"namespaces\":false}","wgNoticeProject":"wikipedia","wgInternalRedirectTargetUrl":"/wiki/Myelodysplastic_syndrome","wgWikibaseItemId":"Q954625"});
}</script><script>if(window.mw){
mw.loader.implement("user.options",function($,jQuery){mw.user.options.set({"variant":"en"});});
/* cache key: global:resourceloader:filter:minify-js:7:b2706269305541eba923c165462b22c4 */
}</script>
<script>if(window.mw){
mw.loader.implement("user.tokens",function($,jQuery){mw.user.tokens.set({"editToken":"+\\","patrolToken":"+\\","watchToken":"+\\"});});
}</script>
<script>if(window.mw){
mw.loader.load(["mediawiki.action.view.redirect","mediawiki.page.startup","mediawiki.legacy.wikibits","mediawiki.legacy.ajax","ext.centralauth.centralautologin","mmv.head","ext.imageMetrics.head","ext.visualEditor.viewPageTarget.init","ext.uls.init","ext.uls.interface","ext.centralNotice.bannerController","skins.vector.js"]);
}</script>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 7]><style type="text/css">body{behavior:url("/w/static/1.26wmf13/skins/Vector/csshover.min.htc")}</style><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Myelodysplastic_syndrome skin-vector action-view">
		<div id="mw-page-base" class="noprint"></div>
		<div id="mw-head-base" class="noprint"></div>
		<div id="content" class="mw-body" role="main">
			<a id="top"></a>

							<div id="siteNotice"><!-- CentralNotice --></div>
						<div class="mw-indicators">
</div>
			<h1 id="firstHeading" class="firstHeading" lang="en">Myelodysplastic syndrome</h1>
									<div id="bodyContent" class="mw-body-content">
									<div id="siteSub">From Wikipedia, the free encyclopedia</div>
								<div id="contentSub"><span class="mw-redirectedfrom">  (Redirected from <a href="/w/index.php?title=Myelodysplastic_syndromes&amp;redirect=no" title="Myelodysplastic syndromes">Myelodysplastic syndromes</a>)</span></div>
												<div id="jump-to-nav" class="mw-jump">
					Jump to:					<a href="#mw-head">navigation</a>, 					<a href="#p-search">search</a>
				</div>
				<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><table class="infobox" style="width:22em">
<tr>
<th colspan="2" style="text-align:center;font-size:125%;font-weight:bold;background-color: lightgrey">Myelodysplastic syndrome</th>
</tr>
<tr>
<th colspan="2" style="text-align:center">Classification and external resources</th>
</tr>
<tr>
<th scope="row"><a href="/wiki/Specialty_(medicine)" title="Specialty (medicine)">Specialty</a></th>
<td><a href="/wiki/Haematology" title="Haematology" class="mw-redirect">Haematology</a>, <a href="/wiki/Oncology" title="Oncology">oncology</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/ICD-10" title="ICD-10">10</a></th>
<td><a rel="nofollow" class="external text" href="http://apps.who.int/classifications/icd10/browse/2015/en#/D46">D46</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Statistical_Classification_of_Diseases_and_Related_Health_Problems" title="International Statistical Classification of Diseases and Related Health Problems">ICD</a>-<a href="/wiki/List_of_ICD-9_codes" title="List of ICD-9 codes">9-CM</a></th>
<td><a rel="nofollow" class="external text" href="http://www.icd9data.com/getICD9Code.ashx?icd9=238.7">238.7</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/International_Classification_of_Diseases_for_Oncology" title="International Classification of Diseases for Oncology">ICD-O</a></th>
<td>9980/0-<a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I99893/">9989/3</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Diseases_Database" title="Diseases Database">DiseasesDB</a></th>
<td><a rel="nofollow" class="external text" href="http://www.diseasesdatabase.com/ddb8604.htm">8604</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/EMedicine" title="EMedicine">eMedicine</a></th>
<td><a rel="nofollow" class="external text" href="http://www.emedicine.com/med/topic2695.htm">med/2695</a> <a rel="nofollow" class="external text" href="http://www.emedicine.com/ped/topic1527.htm#">ped/1527</a></td>
</tr>
<tr>
<th scope="row"><a href="/wiki/Medical_Subject_Headings" title="Medical Subject Headings">MeSH</a></th>
<td><a rel="nofollow" class="external text" href="//www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&amp;term=D009190">D009190</a></td>
</tr>
</table>
<p>The <b>myelodysplastic syndromes</b> (also known as MDS or myelodysplasia) are <a href="/wiki/Hematology" title="Hematology">hematological</a> (i.e., blood-related) medical conditions with ineffective production (or "<a href="/wiki/Dysplasia" title="Dysplasia">dysplasia</a>") of all blood cells.<sup id="cite_ref-1" class="reference"><a href="#cite_note-1"><span>[</span>1<span>]</span></a></sup></p>
<p>Patients with MDS can develop severe <a href="/wiki/Anemia" title="Anemia">anemia</a> and require <a href="/wiki/Blood_transfusion" title="Blood transfusion">blood transfusions</a>. In some cases, the disease worsens and the patient develops <a href="/wiki/Cytopenia" title="Cytopenia">cytopenias</a> (low blood counts) caused by progressive <a href="/wiki/Bone_marrow" title="Bone marrow">bone marrow</a> failure.</p>
<p>The outlook in MDS depends on the type and severity. Many people live normal lifespans with MDS. Often, people are asymptomatic and are unaware they have MDS until it shows up in a routine blood test.</p>
<p>The myelodysplastic syndromes are all disorders of the <a href="/wiki/Hematopoietic_stem_cell" title="Hematopoietic stem cell">hematopoietic stem cells</a> in the bone marrow (only related to myeloid lineage).<sup id="cite_ref-2" class="reference"><a href="#cite_note-2"><span>[</span>2<span>]</span></a></sup> In MDS, <a href="/wiki/Hematopoiesis" title="Hematopoiesis" class="mw-redirect">hematopoiesis</a> (i.e., blood production) is disorderly and ineffective. The number and quality of blood-forming cells decline irreversibly, further impairing blood production. The mean age of onset of MDS is 68 years.</p>
<p></p>
<div id="toc" class="toc">
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Classification"><span class="tocnumber">1</span> <span class="toctext">Classification</span></a>
<ul>
<li class="toclevel-2 tocsection-2"><a href="#French-American-British_.28FAB.29_classification"><span class="tocnumber">1.1</span> <span class="toctext">French-American-British (FAB) classification</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#World_Health_Organization"><span class="tocnumber">1.2</span> <span class="toctext">World Health Organization</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Myelodysplastic_syndrome_unclassified"><span class="tocnumber">1.3</span> <span class="toctext">Myelodysplastic syndrome unclassified</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-5"><a href="#Signs_and_symptoms"><span class="tocnumber">2</span> <span class="toctext">Signs and symptoms</span></a></li>
<li class="toclevel-1 tocsection-6"><a href="#Pathophysiology"><span class="tocnumber">3</span> <span class="toctext">Pathophysiology</span></a>
<ul>
<li class="toclevel-2 tocsection-7"><a href="#Genetics"><span class="tocnumber">3.1</span> <span class="toctext">Genetics</span></a></li>
<li class="toclevel-2 tocsection-8"><a href="#5q-_syndrome"><span class="tocnumber">3.2</span> <span class="toctext">5q- syndrome</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Splicing_factor_mutations"><span class="tocnumber">3.3</span> <span class="toctext">Splicing factor mutations</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-10"><a href="#Diagnosis"><span class="tocnumber">4</span> <span class="toctext">Diagnosis</span></a></li>
<li class="toclevel-1 tocsection-11"><a href="#Management"><span class="tocnumber">5</span> <span class="toctext">Management</span></a></li>
<li class="toclevel-1 tocsection-12"><a href="#Prognosis"><span class="tocnumber">6</span> <span class="toctext">Prognosis</span></a></li>
<li class="toclevel-1 tocsection-13"><a href="#Epidemiology"><span class="tocnumber">7</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1 tocsection-14"><a href="#History"><span class="tocnumber">8</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1 tocsection-15"><a href="#Famous_patients"><span class="tocnumber">9</span> <span class="toctext">Famous patients</span></a></li>
<li class="toclevel-1 tocsection-16"><a href="#References"><span class="tocnumber">10</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-17"><a href="#External_links"><span class="tocnumber">11</span> <span class="toctext">External links</span></a></li>
<li class="toclevel-1 tocsection-18"><a href="#See_also"><span class="tocnumber">12</span> <span class="toctext">See also</span></a></li>
</ul>
</div>
<p></p>
<h2><span class="mw-headline" id="Classification">Classification</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=1" title="Edit section: Classification">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<h3><span class="mw-headline" id="French-American-British_.28FAB.29_classification">French-American-British (FAB) classification</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=2" title="Edit section: French-American-British (FAB) classification">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In 1974 and 1975, a group of pathologists from France, the US, and Britain produced the first widely used classification of these diseases. This <a href="/wiki/French-American-British_classification" title="French-American-British classification" class="mw-redirect">French-American-British classification</a> was published in 1976,<sup id="cite_ref-pmid188440_3-0" class="reference"><a href="#cite_note-pmid188440-3"><span>[</span>3<span>]</span></a></sup> and revised in 1982. It was used by pathologists and clinicians for almost 20 years. Cases were classified into five categories:</p>
<table class="wikitable">
<tr>
<th><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">ICD-O</a></th>
<th>Name</th>
<th>Description</th>
</tr>
<tr>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I99803/">9980/3</a></td>
<td><a href="/wiki/Refractory_anemia" title="Refractory anemia" class="mw-redirect">Refractory anemia</a> (RA)</td>
<td>characterized by less than 5% primitive blood cells (<a href="/wiki/Myeloblasts" title="Myeloblasts" class="mw-redirect">myeloblasts</a>) in the bone marrow and pathological abnormalities primarily seen in red cell precursors</td>
</tr>
<tr>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I99823/">9982/3</a></td>
<td><a href="/wiki/Refractory_anemia_with_ring_sideroblasts" title="Refractory anemia with ring sideroblasts">Refractory anemia with ring sideroblasts</a> (RARS)</td>
<td>also characterized by less than 5% myeloblasts in the bone marrow, but distinguished by the presence of 15% or greater red cell precursors in the marrow being abnormal iron-stuffed cells called "ringed sideroblasts"</td>
</tr>
<tr>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I99833/">9983/3</a></td>
<td><a href="/wiki/Refractory_anemia_with_excess_blasts" title="Refractory anemia with excess blasts" class="mw-redirect">Refractory anemia with excess blasts</a> (RAEB)</td>
<td>characterized by 5-20% myeloblasts in the marrow</td>
</tr>
<tr>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I99843/">9984/3</a></td>
<td><a href="/wiki/Refractory_anemia_with_excess_blasts_in_transformation" title="Refractory anemia with excess blasts in transformation" class="mw-redirect">Refractory anemia with excess blasts in transformation</a> (RAEB-T)</td>
<td>characterized by 21-30% myeloblasts in the marrow (&gt;30% blasts is defined as <a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">acute myeloid leukemia</a>)</td>
</tr>
<tr>
<td><a href="/wiki/ICD-O" title="ICD-O" class="mw-redirect">M</a><a rel="nofollow" class="external text" href="http://www.progenetix.net/progenetix/I99453/">9945/3</a></td>
<td><a href="/wiki/Chronic_myelomonocytic_leukemia" title="Chronic myelomonocytic leukemia">Chronic myelomonocytic leukemia</a> (CMML), not to be confused with <a href="/wiki/Chronic_myelogenous_leukemia" title="Chronic myelogenous leukemia">chronic myelogenous leukemia</a> or CML</td>
<td>characterized by less than 20% myeloblasts in the bone marrow and greater than 1*10<sup>9</sup>/L <a href="/wiki/Monocytes" title="Monocytes" class="mw-redirect">monocytes</a> (a type of white blood cell) circulating in the peripheral blood.</td>
</tr>
</table>
<p>(A table comparing these is available from the <a href="/wiki/Cleveland_Clinic" title="Cleveland Clinic">Cleveland Clinic</a>.<sup id="cite_ref-urlTable_1:_French-American-British_.28FAB.29_Classification_of_MDS_4-0" class="reference"><a href="#cite_note-urlTable_1:_French-American-British_.28FAB.29_Classification_of_MDS-4"><span>[</span>4<span>]</span></a></sup>)</p>
<p>The best prognosis is seen with RA and RARS, where some non-transplant patients live more than a decade (the average is on the order of three to five years, although long-term remission is possible if a bone marrow transplant is successful). The worst outlook is with RAEB-T, where the mean life expectancy is less than 1 year. About one quarter of patients develop overt <a href="/wiki/Leukemia" title="Leukemia">leukemia</a>. The others die of complications of low blood count or unrelated disease. The <i><a href="/wiki/International_Prognostic_Scoring_System" title="International Prognostic Scoring System">International Prognostic Scoring System</a></i> is another tool for determining the prognosis of MDS, published in <i>Blood</i> in 1997.<sup id="cite_ref-5" class="reference"><a href="#cite_note-5"><span>[</span>5<span>]</span></a></sup> This system takes into account the percentage of blasts in the marrow, cytogenetics, and number of cytopenias.</p>
<h3><span class="mw-headline" id="World_Health_Organization">World Health Organization</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=3" title="Edit section: World Health Organization">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>In the late 1990s a group of pathologists and clinicians working under the <a href="/wiki/World_Health_Organization" title="World Health Organization">World Health Organization</a> (WHO) modified this classification, introducing several new disease categories and eliminating others. Most recently, the WHO has evolved a new classification scheme (2008) which is based more on genetic findings. However, morphology of the cells in the peripheral blood, bone marrow aspirate, and bone marrow biopsy is still the screening test used in order to decide which classification is best and which cytogenetic aberrations may be related.</p>
<p>The list of dysplastic syndromes under the new WHO system includes:</p>
<table class="wikitable">
<tr>
<th>Old system</th>
<th>New system</th>
</tr>
<tr>
<td><a href="/wiki/Refractory_anemia#Refractory_anemia" title="Refractory anemia" class="mw-redirect">Refractory anemia</a> (RA)</td>
<td>Refractory <a href="/wiki/Cytopenia" title="Cytopenia">cytopenia</a> with unilineage dysplasia (Refractory anemia, <a href="/wiki/Refractory_neutropenia" title="Refractory neutropenia" class="mw-redirect">Refractory neutropenia</a>, and <a href="/wiki/Refractory_thrombocytopenia" title="Refractory thrombocytopenia" class="mw-redirect">Refractory thrombocytopenia</a>)</td>
</tr>
<tr>
<td><a href="/wiki/Refractory_anemia_with_ringed_sideroblasts" title="Refractory anemia with ringed sideroblasts" class="mw-redirect">Refractory anemia with ringed sideroblasts</a> (RARS)</td>
<td>Refractory anemia with ring sideroblasts (RARS)<br />
<br />
Refractory anemia with ring sideroblasts - thrombocytosis (RARS-t) (provisional entity) which is in essence a <a href="/wiki/Myelodysplastic/myeloproliferative_disorder" title="Myelodysplastic/myeloproliferative disorder" class="mw-redirect">myelodysplastic/myeloproliferative disorder</a> and usually has a <a href="/wiki/JAK2" title="JAK2" class="mw-redirect">JAK2</a> mutation (janus kinase) - New WHO classification 2008</td>
</tr>
<tr>
<td></td>
<td><a href="/wiki/Refractory_cytopenia_with_multilineage_dysplasia" title="Refractory cytopenia with multilineage dysplasia">Refractory cytopenia with multilineage dysplasia</a> (RCMD) includes the subset Refractory cytopenia with multilineage dysplasia and ring sideroblasts (RCMD-RS). RCMD includes patients with pathological changes not restricted to red cells (i.e., prominent white cell precursor and platelet precursor (megakaryocyte) dysplasia.</td>
</tr>
<tr>
<td><a href="/wiki/Refractory_anemia_with_excess_blasts" title="Refractory anemia with excess blasts" class="mw-redirect">Refractory anemia with excess blasts</a> (RAEB)</td>
<td>Refractory anemias with excess blasts I and II. RAEB was divided into RAEB-I (5-9% blasts) and RAEB-II (10-19%) blasts, which has a poorer prognosis than RAEB-I. <a href="/wiki/Auer_rods" title="Auer rods" class="mw-redirect">Auer rods</a> may be seen in RAEB-II which may be difficult to distinguish from acute myeloid leukemia.</td>
</tr>
<tr>
<td><a href="/wiki/Refractory_anemia_with_excess_blasts_in_transformation" title="Refractory anemia with excess blasts in transformation" class="mw-redirect">Refractory anemia with excess blasts in transformation</a> (RAEB-T)</td>
<td>This category was eliminated; such patients are now considered to have acute leukemia.
<p><a href="/wiki/5q-_syndrome" title="5q- syndrome" class="mw-redirect">5q- syndrome</a>, typically seen in older women with normal or high platelet counts and isolated deletions of the long arm of chromosome 5 in bone marrow cells, was added to the classification.</p>
</td>
</tr>
<tr>
<td><a href="/wiki/Chronic_myelomonocytic_leukemia" title="Chronic myelomonocytic leukemia">Chronic myelomonocytic leukemia</a> (CMML)</td>
<td>CMML was removed from the myelodysplastic syndromes and put in a new category of <a href="/wiki/Myelodysplastic-myeloproliferative" title="Myelodysplastic-myeloproliferative" class="mw-redirect">myelodysplastic-myeloproliferative</a> overlap syndromes.</td>
</tr>
<tr>
<td></td>
<td>Myelodysplasia unclassifiable (seen in those cases of megakaryocyte dysplasia with fibrosis and others)</td>
</tr>
<tr>
<td></td>
<td><a href="/wiki/Refractory_cytopenia_of_childhood" title="Refractory cytopenia of childhood">Refractory cytopenia of childhood</a> (dysplasia in childhood) - New in WHO classification 2008</td>
</tr>
</table>
<p>Not all physicians concur with this reclassification, because the underlying pathology of the diseases is not well understood.</p>
<h3><span class="mw-headline" id="Myelodysplastic_syndrome_unclassified">Myelodysplastic syndrome unclassified</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=4" title="Edit section: Myelodysplastic syndrome unclassified">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>WHO-proposed criteria for diagnosis and classification of MDS apply to most cases. However, occasional cases are difficult to classify into defined categories because of one or more unusual features:</p>
<ul>
<li>Rare cases with less than 5% blast will present with <a href="/wiki/Auer_rod" title="Auer rod">auer rods</a>. These cases usually have the features of RAMD.</li>
<li>Occasionally cases of MDS present with isolated neutropenia or thrombocytopenia without anemia and with dysplastic changes confined to the single lineage. The term refractory neutropenia and refractory thrombocytopenia have sometimes used to describe these cases. A diagnosis of MDS in patients with neutropenia or thromobocytopenia without anemia should be made with caution.</li>
<li>Patients with RA or RAEB occasionally present with leukocytosis or thrombocytosis instead of usual cytopenia.</li>
</ul>
<h2><span class="mw-headline" id="Signs_and_symptoms">Signs and symptoms</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=5" title="Edit section: Signs and symptoms">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Tumor_Myelodysplastic_Spleen.JPG" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/8/89/Tumor_Myelodysplastic_Spleen.JPG/220px-Tumor_Myelodysplastic_Spleen.JPG" width="220" height="186" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/8/89/Tumor_Myelodysplastic_Spleen.JPG/330px-Tumor_Myelodysplastic_Spleen.JPG 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/8/89/Tumor_Myelodysplastic_Spleen.JPG/440px-Tumor_Myelodysplastic_Spleen.JPG 2x" data-file-width="540" data-file-height="456" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Tumor_Myelodysplastic_Spleen.JPG" class="internal" title="Enlarge"></a></div>
Enlarged spleen due to myelodysplastic syndrome; CT scan coronal section. Spleen in red, left kidney in green.</div>
</div>
</div>
<p>The median age at diagnosis of a MDS is between 60 and 75 years; a few patients are younger than 50; MDS diagnoses are rare in children. Males are slightly more commonly affected than females. Signs and symptoms are nonspecific and generally related to the blood cytopenias:</p>
<ul>
<li><a href="/wiki/Anemia" title="Anemia">Anemia</a> (low <a href="/wiki/Red_blood_cell" title="Red blood cell">RBC</a> count or reduced <a href="/wiki/Hemoglobin" title="Hemoglobin">hemoglobin</a>) —chronic tiredness, shortness of breath, chilled sensation, sometimes chest pain;</li>
<li><a href="/wiki/Neutropenia" title="Neutropenia">Neutropenia</a> (low neutrophil count) —increased susceptibility to <a href="/wiki/Infection" title="Infection">infection</a>;</li>
<li><a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">Thrombocytopenia</a> (low platelet count) —increased susceptibility to <a href="/wiki/Bleeding" title="Bleeding">bleeding</a> and <a href="/wiki/Ecchymosis" title="Ecchymosis">ecchymosis</a> (bruising), as well as subcutaneous <a href="/wiki/Hemorrhage" title="Hemorrhage" class="mw-redirect">hemorrhaging</a> resulting in <a href="/wiki/Purpura" title="Purpura">purpura</a> or <a href="/wiki/Petechia" title="Petechia">petechia</a>.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6"><span>[</span>6<span>]</span></a></sup></li>
</ul>
<p>Many individuals are asymptomatic, and blood cytopenia or other problems are identified as a part of a routine blood count:</p>
<ul>
<li><a href="/wiki/Neutropenia" title="Neutropenia">neutropenia</a>, <a href="/wiki/Anemia" title="Anemia">anemia</a> and <a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">thrombocytopenia</a> (low cell counts of white and red blood cells, and platelets, respectively);</li>
<li><a href="/wiki/Splenomegaly" title="Splenomegaly">splenomegaly</a> or rarely <a href="/wiki/Hepatomegaly" title="Hepatomegaly">hepatomegaly</a>;</li>
<li>abnormal granules in cells, abnormal nuclear shape and size; and/or</li>
<li><a href="/wiki/Chromosome" title="Chromosome">chromosomal</a> abnormalities, including <a href="/wiki/Chromosomal_translocation" title="Chromosomal translocation">chromosomal translocations</a> and abnormal chromosome number.</li>
</ul>
<p>Although there is some risk for developing <a href="/wiki/Acute_myelogenous_leukemia" title="Acute myelogenous leukemia" class="mw-redirect">acute myelogenous leukemia</a>, about 50% of deaths occur as a result of bleeding or infection. However, leukemia that occurs as a result of myelodysplasia is notoriously resistant to treatment.</p>
<h2><span class="mw-headline" id="Pathophysiology">Pathophysiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=6" title="Edit section: Pathophysiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>MDS is caused by environmental exposures such as radiation and <a href="/wiki/Benzene" title="Benzene">benzene</a>; other risk factors have been inconsistently reported. However, definitive proof of specific causes cannot be determined. Secondary MDS occurs as a late toxicity of cancer treatment, usually with a combination of radiation and the radiomimetic alkylating agents such as <a href="/wiki/Busulfan" title="Busulfan">busulfan</a>, <a href="/wiki/Nitrosourea" title="Nitrosourea">nitrosourea</a>, or <a href="/wiki/Procarbazine" title="Procarbazine">procarbazine</a> (with a latent period of 5 to 7 years) or the <a href="/w/index.php?title=DNA_topoisomerase_inhibitor&amp;action=edit&amp;redlink=1" class="new" title="DNA topoisomerase inhibitor (page does not exist)">DNA topoisomerase inhibitors</a> (2 years). Both <a href="/w/index.php?title=Acquired_aplastic_anemia&amp;action=edit&amp;redlink=1" class="new" title="Acquired aplastic anemia (page does not exist)">acquired aplastic anemia</a> following immunosuppressive treatment and <a href="/wiki/Fanconi%27s_anemia" title="Fanconi's anemia" class="mw-redirect">Fanconi's anemia</a> can evolve into MDS.</p>
<p>MDS is thought to arise from <a href="/wiki/Mutation" title="Mutation">mutations</a> in the <a href="/wiki/Hematopoietic_stem_cell" title="Hematopoietic stem cell">multi-potent bone marrow stem cell</a>, but the specific defects responsible for these diseases remain poorly understood. <a href="/wiki/Cellular_differentiation" title="Cellular differentiation">Differentiation</a> of blood precursor cells is impaired, and there is a significant increase in levels of <a href="/wiki/Apoptosis" title="Apoptosis">apoptotic</a> cell death in bone marrow cells. Clonal expansion of the abnormal cells results in the production of cells which have lost the ability to differentiate. If the overall percentage of bone marrow <a href="/wiki/Myeloblast" title="Myeloblast">myeloblasts</a> rises over a particular cutoff (20% for <a href="/wiki/Myelodysplastic#World_Health_Organization" title="Myelodysplastic" class="mw-redirect">WHO</a> and 30% for <a href="/wiki/Myelodysplastic#French-American-British_.28FAB.29_classification" title="Myelodysplastic" class="mw-redirect">FAB</a>), then transformation to <a href="/wiki/Acute_myelogenous_leukemia" title="Acute myelogenous leukemia" class="mw-redirect">acute myelogenous leukemia</a> (AML) is said to have occurred. The progression of MDS to AML is a good example of the <i><a href="/wiki/Knudson_hypothesis" title="Knudson hypothesis">multi-step theory of carcinogenesis</a></i> in which a series of mutations occur in an initially normal cell and transform it into a <a href="/wiki/Cancer" title="Cancer">cancer</a> cell.</p>
<p>While recognition of leukemic transformation was historically important (see <a href="/wiki/Myelodysplastic#History" title="Myelodysplastic" class="mw-redirect">History</a>), a significant proportion of the <a href="/wiki/Morbidity" title="Morbidity" class="mw-redirect">morbidity</a> and <a href="/wiki/Death" title="Death">mortality</a> attributable to MDS results not from transformation to AML but rather from the cytopenias seen in all MDS patients. While anemia is the most common <a href="/wiki/Cytopenia" title="Cytopenia">cytopenia</a> in MDS patients, given the ready availability of <a href="/wiki/Blood_transfusion" title="Blood transfusion">blood transfusion</a>, MDS patients rarely suffer injury from severe anemia. The two most serious complications in MDS patients resulting from their <a href="/wiki/Cytopenia" title="Cytopenia">cytopenias</a> are bleeding (due to lack of <a href="/wiki/Platelet" title="Platelet">platelets</a>) or infection (due to lack of <a href="/wiki/White_blood_cell" title="White blood cell">white blood cells</a>). Long-term transfusion of <a href="/wiki/Packed_red_blood_cells" title="Packed red blood cells">packed red blood cells</a> leads to <a href="/wiki/Iron_overload#Secondary_haemochromatosis" title="Iron overload">iron overload</a>.</p>
<h3><span class="mw-headline" id="Genetics">Genetics</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=7" title="Edit section: Genetics">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>The recognition of <a href="/wiki/Epigenetic" title="Epigenetic" class="mw-redirect">epigenetic</a> changes in <a href="/wiki/DNA" title="DNA">DNA</a> structure in MDS has explained the success of two of three commercially available medications approved by the <a href="/wiki/Food_and_Drug_Administration_(United_States)" title="Food and Drug Administration (United States)" class="mw-redirect">U.S. Food and Drug Administration</a> (FDA) to treat MDS. Proper <a href="/wiki/DNA_methylation" title="DNA methylation">DNA methylation</a> is critical in the regulation of proliferation genes, and the loss of DNA methylation control can lead to uncontrolled cell growth, and cytopenias. The recently approved <a href="/w/index.php?title=DNA_methyltransferase_inhibitors&amp;action=edit&amp;redlink=1" class="new" title="DNA methyltransferase inhibitors (page does not exist)">DNA methyltransferase inhibitors</a> take advantage of this mechanism by creating a more orderly DNA methylation profile in the <a href="/wiki/Hematopoietic_stem_cell" title="Hematopoietic stem cell">hematopoietic stem cell</a> <a href="/wiki/Cell_nucleus" title="Cell nucleus">nucleus</a>, and thereby restore normal blood counts and retard the progression of MDS to <a href="/wiki/Acute_leukemia" title="Acute leukemia">acute leukemia</a>.</p>
<p>Some authors have proposed that the loss of <a href="/wiki/Mitochondrial" title="Mitochondrial" class="mw-redirect">mitochondrial</a> function over time leads to the accumulation of <a href="/wiki/DNA_mutations" title="DNA mutations" class="mw-redirect">DNA mutations</a> in hematopoietic stem cells, and this accounts for the increased incidence of MDS in older patients. Researchers point to the accumulation of mitochondrial <a href="/wiki/Iron" title="Iron">iron</a> deposits in the <a href="/wiki/Ringed_sideroblast" title="Ringed sideroblast" class="mw-redirect">ringed sideroblast</a> as evidence of <a href="/wiki/Mitochondrial" title="Mitochondrial" class="mw-redirect">mitochondrial</a> dysfunction in MDS.<sup id="cite_ref-pmid12406866_7-0" class="reference"><a href="#cite_note-pmid12406866-7"><span>[</span>7<span>]</span></a></sup></p>
<h3><span class="mw-headline" id="5q-_syndrome">5q- syndrome</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=8" title="Edit section: 5q- syndrome">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Since at least 1974, the deletion in the long arm of <a href="/wiki/Chromosome_5" title="Chromosome 5" class="mw-redirect">chromosome 5</a> has been associated with dysplastic abnormalities of hematopoietic stem cells.<sup id="cite_ref-pmid3552346_8-0" class="reference"><a href="#cite_note-pmid3552346-8"><span>[</span>8<span>]</span></a></sup><sup id="cite_ref-pmid4421285_9-0" class="reference"><a href="#cite_note-pmid4421285-9"><span>[</span>9<span>]</span></a></sup> By 2005, it was recognized that <a href="/wiki/Lenalidomide" title="Lenalidomide">lenalidomide</a> was effective in MDS patients with the <a href="/wiki/5q-_syndrome" title="5q- syndrome" class="mw-redirect">5q- syndrome</a>,<sup id="cite_ref-pmid15703420_10-0" class="reference"><a href="#cite_note-pmid15703420-10"><span>[</span>10<span>]</span></a></sup> and in December 2005, the US FDA approved the drug for this indication. Patients with isolated 5q-, low IPSS risk, and transfusion dependence respond best to lenalidomide. Typically, prognosis for these patients is favorable, with 63 months median survival. Lenalidomide has dual action: by lowering the malignant clone number in patients with 5q-, and by inducing better differentiation of healthy erythroid cells, as seen in patients without 5q deletion.</p>
<h3><span class="mw-headline" id="Splicing_factor_mutations">Splicing factor mutations</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=9" title="Edit section: Splicing factor mutations">edit</a><span class="mw-editsection-bracket">]</span></span></h3>
<p>Mutations in splicing factors have been found in 40-80% of cases with myelodysplastic syndrome, particularly in those with ringed sideroblasts.<sup id="cite_ref-Rozovski2012_11-0" class="reference"><a href="#cite_note-Rozovski2012-11"><span>[</span>11<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Diagnosis">Diagnosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=10" title="Edit section: Diagnosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>MDS must be differentiated from <a href="/wiki/Anemia" title="Anemia">anemia</a>, <a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">thrombocytopenia</a>, and/or <a href="/wiki/Leukopenia" title="Leukopenia">leukopenia</a>. Usually, the elimination of other causes of these <a href="/wiki/Cytopenias" title="Cytopenias" class="mw-redirect">cytopenias</a>, along with a <a href="/wiki/Dysplastic" title="Dysplastic" class="mw-redirect">dysplastic</a> bone marrow, is required to diagnose a myelodysplastic syndrome.</p>
<div class="thumb tright">
<div class="thumbinner" style="width:222px;"><a href="/wiki/File:Hypogranular_neutrophil_with_a_pseudo-Pelger-Huet_nucleus_in_MDS.jpg" class="image"><img alt="" src="//upload.wikimedia.org/wikipedia/commons/thumb/0/02/Hypogranular_neutrophil_with_a_pseudo-Pelger-Huet_nucleus_in_MDS.jpg/220px-Hypogranular_neutrophil_with_a_pseudo-Pelger-Huet_nucleus_in_MDS.jpg" width="220" height="314" class="thumbimage" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/0/02/Hypogranular_neutrophil_with_a_pseudo-Pelger-Huet_nucleus_in_MDS.jpg/330px-Hypogranular_neutrophil_with_a_pseudo-Pelger-Huet_nucleus_in_MDS.jpg 1.5x, //upload.wikimedia.org/wikipedia/commons/0/02/Hypogranular_neutrophil_with_a_pseudo-Pelger-Huet_nucleus_in_MDS.jpg 2x" data-file-width="359" data-file-height="512" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:Hypogranular_neutrophil_with_a_pseudo-Pelger-Huet_nucleus_in_MDS.jpg" class="internal" title="Enlarge"></a></div>
Blood smear from an adult female with a myelodysplastic syndrome related to radiotherapy and chemotherapy for Hodgkin disease. A hypogranular neutrophil with a pseudo-Pelger-Huet nucleus is shown. The red blood cells show marked poikilocytosis, in part related to post-splenectomy status. (Wright-Giemsa stain).</div>
</div>
</div>
<p>A typical investigation includes:</p>
<ul>
<li><a href="/wiki/Full_blood_count" title="Full blood count" class="mw-redirect">Full blood count</a> and examination of <a href="/wiki/Blood_film" title="Blood film">blood film</a>. The blood film morphology can provide clues about <a href="/wiki/Hemolytic_anemia" title="Hemolytic anemia">hemolytic anemia</a>, clumping of the <a href="/wiki/Platelets" title="Platelets" class="mw-redirect">platelets</a> leading to spurious <a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">thrombocytopenia</a>, or <a href="/wiki/Leukemia" title="Leukemia">leukemia</a>.</li>
<li>Blood tests to eliminate other common causes of <a href="/wiki/Cytopenias" title="Cytopenias" class="mw-redirect">cytopenias</a>, such as <a href="/wiki/Lupus_erythematosus" title="Lupus erythematosus">lupus</a>, <a href="/wiki/Hepatitis" title="Hepatitis">hepatitis</a>, <a href="/wiki/Vitamin_B12" title="Vitamin B12">B<sub>12</sub></a>, <a href="/wiki/Folate" title="Folate" class="mw-redirect">folate</a>, or other <a href="/wiki/Vitamin" title="Vitamin">vitamin</a> deficiencies, <a href="/wiki/Renal_failure" title="Renal failure">renal failure</a> or <a href="/wiki/Heart_failure" title="Heart failure">heart failure</a>, <a href="/wiki/HIV" title="HIV">HIV</a>, <a href="/wiki/Hemolytic_anemia" title="Hemolytic anemia">hemolytic anemia</a>, <a href="/wiki/Monoclonal_gammopathy" title="Monoclonal gammopathy">monoclonal gammopathy</a>. Age-appropriate <a href="/wiki/Cancer_screening" title="Cancer screening">cancer screening</a> should be considered for all <a href="/wiki/Anemic" title="Anemic" class="mw-redirect">anemic</a> patients.</li>
<li><a href="/wiki/Bone_marrow_examination" title="Bone marrow examination">Bone marrow examination</a> by a <a href="/wiki/Hematopathologist" title="Hematopathologist" class="mw-redirect">hematopathologist</a>. This is required to establish the diagnosis, since all hematopathologists consider dysplastic marrow the key feature of myelodysplasia.</li>
<li><a href="/wiki/Cytogenetics" title="Cytogenetics">Cytogenetics</a> or chromosomal studies. This is ideally performed on the bone marrow aspirate. Conventional cytogenetics requires a fresh specimen, since live cells are induced to enter <a href="/wiki/Metaphase" title="Metaphase">metaphase</a> to allow chromosomes to be seen.</li>
<li>Interphase <a href="/wiki/Fluorescence_in_situ_hybridization" title="Fluorescence in situ hybridization">FISH</a> testing, usually ordered together with conventional cytogenetic testing, offers rapid detection of several chromosome abnormalities associated with MDS including del 5q, -7, +8, and del 20q.</li>
<li><a href="/wiki/Virtual_Karyotype" title="Virtual Karyotype" class="mw-redirect">Virtual karyotyping</a> can be done for MDS,<sup id="cite_ref-12" class="reference"><a href="#cite_note-12"><span>[</span>12<span>]</span></a></sup> which uses computational tools to construct the karyogram from disrupted DNA. Virtual karyotyping does not require cell culture and has dramatically higher resolution than conventional cytogenetics, but cannot detect balanced translocations.</li>
<li><a href="/wiki/Flow_cytometry" title="Flow cytometry">Flow cytometry</a> is helpful to establish the presence of any <a href="/wiki/Lymphoproliferative" title="Lymphoproliferative" class="mw-redirect">lymphoproliferative</a> disorder in the marrow.</li>
<li>Testing for copper deficiency should not be overlooked, as it can morphologically resemble MDS in bone marrow biopsies.<sup id="cite_ref-13" class="reference"><a href="#cite_note-13"><span>[</span>13<span>]</span></a></sup></li>
</ul>
<p>Anemia dominates the early course. Most symptomatic patients complain of the gradual onset of fatigue and weakness, <a href="/wiki/Dyspnea" title="Dyspnea">dyspnea</a>, and <a href="/wiki/Pallor" title="Pallor">pallor</a>, but at least half the patients are asymptomatic and their MDS is discovered only incidentally on routine blood counts. Previous chemotherapy or radiation exposure is an important historic fact. Fever and weight loss should point to a myeloproliferative rather than myelodysplastic process. Children with <a href="/wiki/Down_syndrome" title="Down syndrome">Down syndrome</a> are susceptible to MDS, and a family history may indicate a hereditary form of <a href="/wiki/Sideroblastic_anemia" title="Sideroblastic anemia">sideroblastic anemia</a> or <a href="/wiki/Fanconi_anemia" title="Fanconi anemia">Fanconi anemia</a>.</p>
<p>The average age at diagnosis for MDS is about 65 years, but pediatric cases have been reported. Some patients have a history of exposure to chemotherapy (especially alkylating agents such as <a href="/wiki/Melphalan" title="Melphalan">melphalan</a>, <a href="/wiki/Cyclophosphamide" title="Cyclophosphamide">cyclophosphamide</a>, <a href="/wiki/Busulfan" title="Busulfan">busulfan</a>, and <a href="/wiki/Chlorambucil" title="Chlorambucil">chlorambucil</a>) or <a href="/wiki/Radiation" title="Radiation">radiation</a> (therapeutic or accidental), or both (e.g., at the time of stem cell transplantation for another disease). Workers in some industries with heavy exposure to hydrocarbons such as the petroleum industry have a slightly higher risk of contracting the disease than the general population. Males are slightly more frequently affected than females. <a href="/wiki/Xylene" title="Xylene">Xylene</a> and benzene exposure has been associated with myelodysplasia. <a href="/wiki/Vietnam_veteran" title="Vietnam veteran">Vietnam veterans</a> exposed to <a href="/wiki/Agent_Orange" title="Agent Orange">Agent Orange</a> are at risk of developing MDS. <a rel="nofollow" class="external text" href="http://jco.ascopubs.org/content/29/4/428.full">A 2010 study</a> by the <a href="/wiki/American_Society_of_Clinical_Oncology" title="American Society of Clinical Oncology">American Society of Clinical Oncology</a> suggests a link between the development of MDS "in atomic bomb survivors 40 to 60 years after radiation exposure" (in this case, referring to people who were in close proximity to the dropping of the atomic bomb in Hiroshima and Nagasaki during World War II).</p>
<p>The features generally used to define a MDS are: blood cytopenias; ineffective hematopoiesis; dyserythropoiesis; dysgranulopoiesis; dysmegakaropoiesis and increased myeloblast.</p>
<p>Dysplasia can affect all three lineages seen in the bone marrow. The best way to diagnose dysplasia is by morphology and special stains (PAS) used on the bone marrow aspirate and peripheral blood smear. Dysplasia in the myeloid series is defined by:</p>
<ul>
<li>Granulocytic series
<ol>
<li>Hypersegmented neutrophils (also seen in Vit B<sub>12</sub>/Folate deficiency)</li>
<li>Hyposegmented neutrophils (Pseudo-Pelger Huet)</li>
<li>Hypogranular neutrophils or pseudo Chediak Higashi large granules</li>
<li>Auer rods - automatically RAEB II (if blast count &lt;5% in the peripheral blood and &lt;10% in the bone marrow aspirate) also note Auer rods may be seen in mature neutrophils in AML with translocation t(8;21)</li>
<li>Dimorphic granules (basophilic and eosinophilic granules) within eosinophils</li>
</ol>
</li>
<li>Erythroid series
<ol>
<li>Binucleated erythroid percursors and karyorrhexis</li>
<li>Erythroid nuclear budding</li>
<li>Erythroid nuclear strings or internuclear bridging (also seen in congenital dyserythropoietic anemias)</li>
<li>Loss of E-cadherin in normoblasts is a sign of aberrancy</li>
<li>PAS (globular in vacuoles or diffuse cytoplasmic staining) within erythroid precursors in the bone marrow aspirate (has no bearing on paraffin fixed bone marrow biopsy). Note: One can see PAS vacuolar positivity in L1 and L2 blasts (AFB classification; the L1 and L2 nomenclature is not used in the WHO classification)</li>
<li>Ringed sideroblasts seen on Prussian blue iron stain (10 or more iron granules encircling 1/3 or more of the nucleus and &gt;15% ringed sideroblasts when counted amongst red cell precursors)</li>
</ol>
</li>
<li>Megakaryocytic series (can be the most subjective)
<ol>
<li>Hyposegmented nuclear features in platelet producing megakaryocytes (lack of lobation)</li>
<li>Hypersegmented (osteoclastic appearing) megakaryocytes</li>
<li>Ballooning of the platelets (seen with interference contrast microscopy)</li>
</ol>
</li>
</ul>
<p>Other stains can help in special cases (PAS and napthol ASD chloroacetate esterase positivity) in eosinophils is a marker of abnormality seen in chronic eosinophilic leukemia and is a sign of aberrancy.</p>
<p>On the bone marrow biopsy high grade dysplasia (RAEB-I and RAEB-II) may show atypical localization of immature precursors (ALIPs) which are islands of immature precursors cells (myeloblasts and promyelcytes) localized to the center of intertrabecular space rather than adjacent to the trabeculae or surrounding arterioles. This morphology can be difficult to recognize from treated leukemia and recovering immature normal marrow elements. Also topographic alteration of the nucleated erythroid cells can be seen in early myelodysplasia (RA and RARS), where normoblasts are seen next to bony trabeculae instead of forming normal interstitially placed erythroid islands.</p>
<p>Myelodysplasia is a diagnosis of exclusion and must be made after proper determination of iron stores, <a href="/wiki/Vitamin" title="Vitamin">vitamin</a> deficiencies, and nutrient deficiencies are ruled out. Also congenital diseases such as <a href="/wiki/Congenital_dyserythropoietic_anemia" title="Congenital dyserythropoietic anemia">congenital dyserythropoietic anemia</a> (CDA I through IV) has been recognized, <a href="/wiki/Sideroblastic_anemia" title="Sideroblastic anemia">Pearson's syndrome (sideroblastic anemia)</a>, <a href="/w/index.php?title=Jordans_anomaly&amp;action=edit&amp;redlink=1" class="new" title="Jordans anomaly (page does not exist)">Jordans anomaly</a> - vacuolization in all cell lines may be seen in <a href="/wiki/Chanarin-Dorfman_syndrome" title="Chanarin-Dorfman syndrome" class="mw-redirect">Chanarin-Dorfman syndrome</a>, ALA (aminolevulinic acid) enzyme deficiency, and other more esoteric enzyme deficiencies are known to give a pseudomyelodysplastic picture in one of the cell lines, however, all three cell lines are never morphologically dysplastic in these entities with the exception of chloramphenicol, <a href="/wiki/Arsenic_toxicity" title="Arsenic toxicity">arsenic toxicity</a> and other poisons.</p>
<p>All of these conditions are characterized by abnormalities in the production of one or more of the cellular components of blood (<a href="/wiki/Red_blood_cell" title="Red blood cell">red cells</a>, <a href="/wiki/White_blood_cell" title="White blood cell">white cells</a> other than <a href="/wiki/Lymphocyte" title="Lymphocyte">lymphocytes</a> and <a href="/wiki/Platelets" title="Platelets" class="mw-redirect">platelets</a> or their progenitor cells, <a href="/wiki/Megakaryocyte" title="Megakaryocyte">megakaryocytes</a>).</p>
<h2><span class="mw-headline" id="Management">Management</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=11" title="Edit section: Management">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The goals of therapy are to control symptoms, improve quality of life, improve overall survival, and decrease progression to <a href="/wiki/Acute_myelogenous_leukemia" title="Acute myelogenous leukemia" class="mw-redirect">acute myelogenous leukemia</a> (AML).</p>
<p>The IPSS scoring<sup id="cite_ref-14" class="reference"><a href="#cite_note-14"><span>[</span>14<span>]</span></a></sup> system can help <a href="/wiki/Triage" title="Triage">triage</a> patients for more aggressive treatment (i.e. <a href="/wiki/Bone_marrow_transplant" title="Bone marrow transplant" class="mw-redirect">bone marrow transplant</a>) as well as help determine the best timing of this therapy.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15"><span>[</span>15<span>]</span></a></sup> Supportive care with blood product support and hematopoeitic growth factors (e.g. <a href="/wiki/Erythropoietin" title="Erythropoietin">erythropoietin</a>) is the mainstay of therapy. The regulatory environment for the use of erythropoietins is evolving, according to a recent <a href="/wiki/Medicare_(United_States)" title="Medicare (United States)">US Medicare</a> <a href="/wiki/National_coverage_determination" title="National coverage determination">National coverage determination</a>. No comment on the use of hematopoeitic growth factors for MDS was made in that document.<sup id="cite_ref-16" class="reference"><a href="#cite_note-16"><span>[</span>16<span>]</span></a></sup></p>
<p>Three agents have been approved by the <a href="/wiki/U.S._Food_and_Drug_Administration" title="U.S. Food and Drug Administration" class="mw-redirect">U.S. Food and Drug Administration</a> (FDA) for the treatment of MDS:</p>
<ol>
<li><a href="/wiki/5-azacytidine" title="5-azacytidine" class="mw-redirect">5-azacytidine</a>: 21 month median survival<sup id="cite_ref-pmid10694544_17-0" class="reference"><a href="#cite_note-pmid10694544-17"><span>[</span>17<span>]</span></a></sup><sup id="cite_ref-pmid11529854_18-0" class="reference"><a href="#cite_note-pmid11529854-18"><span>[</span>18<span>]</span></a></sup><sup id="cite_ref-pmid12011120_19-0" class="reference"><a href="#cite_note-pmid12011120-19"><span>[</span>19<span>]</span></a></sup><sup id="cite_ref-pmid16921040_20-0" class="reference"><a href="#cite_note-pmid16921040-20"><span>[</span>20<span>]</span></a></sup></li>
<li><a href="/wiki/Decitabine" title="Decitabine">Decitabine</a>: Complete response rate reported as high as 43%. A phase I study has shown efficacy in AML when decitabine is combined with <a href="/wiki/Valproic_acid" title="Valproic acid" class="mw-redirect">valproic acid</a>.<sup id="cite_ref-pmid17133405_21-0" class="reference"><a href="#cite_note-pmid17133405-21"><span>[</span>21<span>]</span></a></sup><sup id="cite_ref-pmid16532500_22-0" class="reference"><a href="#cite_note-pmid16532500-22"><span>[</span>22<span>]</span></a></sup><sup id="cite_ref-pmid16882708_23-0" class="reference"><a href="#cite_note-pmid16882708-23"><span>[</span>23<span>]</span></a></sup><sup id="cite_ref-pmid17679729_24-0" class="reference"><a href="#cite_note-pmid17679729-24"><span>[</span>24<span>]</span></a></sup></li>
<li><a href="/wiki/Lenalidomide" title="Lenalidomide">Lenalidomide</a>: Effective in reducing red blood cell transfusion requirement in patients with the chromosome 5q deletion subtype of MDS<sup id="cite_ref-pmid17021321_25-0" class="reference"><a href="#cite_note-pmid17021321-25"><span>[</span>25<span>]</span></a></sup></li>
</ol>
<p><a href="/wiki/Chemotherapy" title="Chemotherapy">Chemotherapy</a> with the <a href="/wiki/DNA_methylation" title="DNA methylation">hypomethylating agents</a> 5-azacytidine and decitabine has been shown to decrease blood transfusion requirements and to retard the progression of MDS to AML. Lenalidomide was approved by the FDA in December 2005 only for use in the <a href="/wiki/5q-_syndrome" title="5q- syndrome" class="mw-redirect">5q- syndrome</a>. In the United States, treatment of MDS with lenalidomide costs about US$9,200 per month.<sup id="cite_ref-pmid16625140_26-0" class="reference"><a href="#cite_note-pmid16625140-26"><span>[</span>26<span>]</span></a></sup></p>
<p><a href="/wiki/Stem_cell_transplantation" title="Stem cell transplantation" class="mw-redirect">Stem cell transplantation</a>, particularly in younger patients (i.e. less than 40 years of age), more severely affected patients, offers the potential for curative therapy. Success of bone marrow transplantation has been found to correlate with severity of MDS as determined by the IPSS score, with patients having a more favorable IPSS score tending to have a more favorable outcome with transplantation.<sup id="cite_ref-27" class="reference"><a href="#cite_note-27"><span>[</span>27<span>]</span></a></sup></p>
<p><a href="/wiki/Iron_overload" title="Iron overload">Iron overload</a> in MDS, red blood cell (RBC) <a href="/wiki/Transfusions" title="Transfusions" class="mw-redirect">transfusions</a> are a major part of the supportive care for anemic MDS patients. Although the specific therapies patients receive may alleviate the RBC transfusion need, many MDS patients may not respond to these treatments and may develop iron overload as well as its consequences.</p>
<p>Patients requiring relatively large numbers of RBC transfusions have experienced adverse effect of chronic iron overload on liver, heart, endocrine functions. It is possible that this organ dysfunction may result from iron overload in patients with MDS and that transfusional iron overload might be a contributor to increased sickness and death in early stage MDS.</p>
<p>For patients requiring many RBC transfusions, <a href="/wiki/Serum_ferritin" title="Serum ferritin" class="mw-redirect">serum ferritin</a> levels, number of RBC transfusions received, and associated organ dysfunction (heart, liver, and pancreas) should be monitored to determine iron levels. Monitoring serum ferritin may also be useful, aiming to decrease ferritin levels to &lt;1000 mcg/L.</p>
<p>There are currently two iron <a href="/wiki/Chelation" title="Chelation">chelators</a> available in the US, <a href="/wiki/Deferoxamine" title="Deferoxamine">deferoxamine</a> (Desferal) for IV use and <a href="/wiki/Deferasirox" title="Deferasirox">deferasirox</a> (Exjade) for oral use. These options now provide potentially useful drugs for treating this iron overload problem. A third chelating agent is available in Europe, <a href="/wiki/Deferiprone" title="Deferiprone">deferiprone</a> for oral use, but not available in the US.</p>
<p><a href="/wiki/Clinical_trials" title="Clinical trials" class="mw-redirect">Clinical trials</a> in the MDS are ongoing with iron chelating agents to address the question of whether iron chelation alters the natural history of patients with MDS who are transfusion dependent. Reversal of some of the consequences of iron overload in MDS by iron chelation therapy have been shown.</p>
<p>Both the MDS Foundation and the <a href="/wiki/National_Comprehensive_Cancer_Network" title="National Comprehensive Cancer Network">National Comprehensive Cancer Network</a> MDS Guidelines Panel have recommended that chelation therapy be considered to decrease iron overload in selected MDS patients. Evidence also suggest there is a potential value to iron chelation in patients who then undergo a stem cell transplant.</p>
<p>Although deferasirox is generally well tolerated (other than episodes of gastrointestinal distress and kidney dysfunction in some patients), recently a safety warning by the FDA and Novartis was added to deferasirox treatment guidelines. Following post-marketing use of deferasirox, there were rare cases of acute <a href="/wiki/Kidney_failure" title="Kidney failure" class="mw-redirect">kidney failure</a> or liver failure, some resulting in death. Due to this, it is recommended that patients be closely monitored on deferasirox therapy prior to the start of therapy and regularly thereafter.</p>
<p>Currently<sup class="noprint Inline-Template Template-Fact" style="white-space:nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed"><span title="This claim needs references to reliable sources. (April 2011)">citation needed</span></a></i>]</sup>, a large international Phase III clinical trial is ongoing comparing treatment of deferasirox to placebo, which should help to establish the clinical value of deferasirox in iron- overloaded MDS patients.</p>
<p>In 2013, an <a href="/wiki/Open-label_trial" title="Open-label trial">open-label</a> phase I clinical trial with <a href="/wiki/APG101" title="APG101">APG101</a> in transfusion-dependent patients with low or intermediate risk MDS was initiated at two clinical sites in Germany. Preclinical experiments have shown that <a href="/wiki/APG101" title="APG101">APG101</a> rescues erythrocyte precursor cells from premature cell death. Therefore, treatment with APG101 is expected to lead to improved erythropoiesis and ameliorated anemia in MDS patients. The primary objective of the study is to examine the safety and tolerability of APG101 as well as the hematologic response in MDS patients.<sup id="cite_ref-28" class="reference"><a href="#cite_note-28"><span>[</span>28<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="Prognosis">Prognosis</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=12" title="Edit section: Prognosis">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The outlook in MDS is variable, with ~30% of patients progressing to refractory <a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">acute myeloid leukemia</a>. The median survival rate varies from years to months, depending on type. Stem cell transplantation offers cure, with survival rates of 50% at 3 years, although older patients do poorly.<sup id="cite_ref-Harrison.27s_29-0" class="reference"><a href="#cite_note-Harrison.27s-29"><span>[</span>29<span>]</span></a></sup></p>
<p><b>Indicators of a good prognosis</b>: Younger age; normal or moderately reduced neutrophil or platelet counts; low blast counts in the bone marrow(&lt;20%) and no blasts in the blood; no Auer rods; ringed sideroblasts; normal karyotypes of mixed karyotypes without complex chromosome abnormalities and in vitro marrow culture- non leukemic growth pattern.</p>
<p><b>Indicators of a poor prognosis</b>: Advanced age; severe neutropenia or thrombocytopenia; high blast count in the bone marrow (20-29%) or blasts in the blood; Auer rods; absence of ringed sideroblasts; abnormal localization or immature granulocyte precursors in bone marrow section all or mostly abnormal karyotypes or complex marrow chromosome abnormalities and in-vitro bone emarrow culture-leukemic growth pattern.</p>
<p><b>Prognosis and karyotype</b>: Good: Normal, -Y, del(5q), del(20q)<br />
Intermediate or variable: +8, other single or double anomalies<br />
Poor; Complex (&gt;3 chromosomal aberrations); chromosome 7 anomalies<br />
<sup id="cite_ref-pmid10691865_30-0" class="reference"><a href="#cite_note-pmid10691865-30"><span>[</span>30<span>]</span></a></sup></p>
<p>The <a href="/wiki/International_Prognostic_Scoring_System" title="International Prognostic Scoring System">International Prognostic Scoring System</a> (IPSS) is the most commonly used tool in MDS to predict long-term outcome.<sup id="cite_ref-31" class="reference"><a href="#cite_note-31"><span>[</span>31<span>]</span></a></sup></p>
<p>Cytogenetic abnormalities can be detected by conventional cytogenetics, a FISH panel for MDS, or <a href="/wiki/Virtual_Karyotype" title="Virtual Karyotype" class="mw-redirect">Virtual Karyotype</a>.</p>
<h2><span class="mw-headline" id="Epidemiology">Epidemiology</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=13" title="Edit section: Epidemiology">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>The exact number of people with MDS is not known because it can go undiagnosed and there is no mandated tracking of the syndrome. Some estimates are on the order of 10,000 to 20,000 new cases each year in the <a href="/wiki/United_States" title="United States">United States</a> alone. The incidence is probably increasing as the age of the population increases, and some authors propose that the incidence in patients over 70 may be as high as 15 cases per 100,000 per year.<sup id="cite_ref-pmid11503953_32-0" class="reference"><a href="#cite_note-pmid11503953-32"><span>[</span>32<span>]</span></a></sup></p>
<h2><span class="mw-headline" id="History">History</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=14" title="Edit section: History">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Since the early 20th century, it began to be recognized that some people with <a href="/wiki/Acute_myelogenous_leukemia" title="Acute myelogenous leukemia" class="mw-redirect">acute myelogenous leukemia</a> had a preceding period of <a href="/wiki/Anemia" title="Anemia">anemia</a> and abnormal <a href="/wiki/Blood_cell" title="Blood cell">blood cell</a> production. These conditions were lumped together with other diseases under the term "refractory anemia". The first description of "preleukemia" as a specific entity was published in 1953 by Block <i>et al.</i><sup id="cite_ref-33" class="reference"><a href="#cite_note-33"><span>[</span>33<span>]</span></a></sup> The early identification, characterization and classification of this disorder were problematical, and the syndrome went by many names until the 1976 FAB classification was published and popularized the term MDS.</p>
<h2><span class="mw-headline" id="Famous_patients">Famous patients</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=15" title="Edit section: Famous patients">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<p>Famous patients with MDS include:</p>
<ul>
<li><a href="/wiki/Astrophysicist" title="Astrophysicist" class="mw-redirect">Astrophysicist</a> <a href="/wiki/Carl_Sagan" title="Carl Sagan">Carl Sagan</a>;</li>
<li><a href="/wiki/Rowing_(sport)" title="Rowing (sport)">Rowing</a> coach <a href="/wiki/Harvard_University" title="Harvard University">Harvard University</a> <a href="/wiki/Harry_Parker_(rower)" title="Harry Parker (rower)">Harry Parker</a>;<sup id="cite_ref-34" class="reference"><a href="#cite_note-34"><span>[</span>34<span>]</span></a></sup></li>
<li>Nobel Chemistry Prize winner <a href="/wiki/Alan_MacDiarmid" title="Alan MacDiarmid">Alan MacDiarmid</a>;</li>
<li>Writer <a href="/wiki/Susan_Sontag" title="Susan Sontag">Susan Sontag</a>;</li>
<li>Writer <a href="/wiki/Nora_Ephron" title="Nora Ephron">Nora Ephron</a>;</li>
<li>Writer <a href="/wiki/Roald_Dahl" title="Roald Dahl">Roald Dahl</a>;</li>
<li>Photographer <a href="/wiki/Mary_Ellen_Mark" title="Mary Ellen Mark">Mary Ellen Mark</a>;</li>
<li>Jazz musicians <a href="/wiki/Michael_Brecker" title="Michael Brecker">Michael Brecker</a>, <a href="/wiki/Joe_Farrell" title="Joe Farrell">Joe Farrell</a> and <a href="/wiki/Paul_Motian" title="Paul Motian">Paul Motian</a>;</li>
<li>Actress <a href="/wiki/Nina_Foch" title="Nina Foch">Nina Foch</a>;</li>
<li>Firearms executive <a href="/wiki/Val_Forgett" title="Val Forgett">Val Forgett</a>;</li>
<li><a href="/wiki/United_States_Congress" title="United States Congress">United States Congressmen</a> <a href="/wiki/Joe_Moakley" title="Joe Moakley">Joe Moakley</a> and <a href="/wiki/Bob_Matsui" title="Bob Matsui">Bob Matsui</a>;</li>
<li>Actor <a href="/wiki/Pat_Hingle" title="Pat Hingle">Pat Hingle</a>;</li>
<li>Actor <a href="/wiki/Larry_Hagman" title="Larry Hagman">Larry Hagman</a>;</li>
<li>Singer and comedienne <a href="/wiki/Fran_Allison" title="Fran Allison">Fran Allison</a>;</li>
<li>Radio personality <a href="/wiki/J.P._McCarthy" title="J.P. McCarthy" class="mw-redirect">J.P. McCarthy</a>;</li>
<li>Danish theoretical physicist <a href="/wiki/Per_Bak" title="Per Bak">Per Bak</a>;</li>
<li>First <a href="/wiki/Scripps_National_Spelling_Bee" title="Scripps National Spelling Bee">National Spelling Bee</a> winner <a href="/wiki/Frank_Neuhauser" title="Frank Neuhauser">Frank Neuhauser</a>;</li>
<li>Good Morning America host <a href="/wiki/Robin_Roberts_(newscaster)" title="Robin Roberts (newscaster)">Robin Roberts</a>;</li>
<li>Actor <a href="/wiki/Amrish_Puri" title="Amrish Puri">Amrish Puri</a>;</li>
<li>Painter Bonnie Lee Butler</li>
<li>Poet <a href="/wiki/Juan_Gelman" title="Juan Gelman">Juan Gelman</a></li>
<li>Professional Hockey Player <a href="/wiki/Doug_Mohns" title="Doug Mohns">Doug Mohns</a></li>
<li>Actor/Comedian <a href="/wiki/Dave_Madden" title="Dave Madden">Dave Madden</a>;</li>
<li>Patient Activist <a href="/w/index.php?title=Lowell_Gene_Moss&amp;action=edit&amp;redlink=1" class="new" title="Lowell Gene Moss (page does not exist)">Lowell Gene Moss</a></li>
</ul>
<h2><span class="mw-headline" id="References">References</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=16" title="Edit section: References">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<div class="reflist columns references-column-width" style="-moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;">
<ol class="references">
<li id="cite_note-1"><span class="mw-cite-backlink"><b><a href="#cite_ref-1">^</a></b></span> <span class="reference-text">"<a rel="nofollow" class="external text" href="http://web.archive.org/web/20090616022448/http://www.mercksource.com/pp/us/cns/cns_hl_dorlands_split.jsp?pg=/ppdocs/us/common/dorlands/dorland/eight/000104509.htm">myelodysplastic syndrome</a>" at <i><a href="/wiki/Dorland%27s_medical_reference_works" title="Dorland's medical reference works">Dorland's Medical Dictionary</a></i></span></li>
<li id="cite_note-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-2">^</a></b></span> <span class="reference-text">page 393 First Aid USMLE 2014, Author Tao Le, McGraw Hill Education</span></li>
<li id="cite_note-pmid188440-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid188440_3-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Bennett JM, Catovsky D, Daniel MT et al. (August 1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". <i>Br. J. Haematol.</i> <b>33</b> (4): 451–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1111%2Fj.1365-2141.1976.tb03563.x">10.1111/j.1365-2141.1976.tb03563.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/188440">188440</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Proposals+for+the+classification+of+the+acute+leukaemias.+French-American-British+%28FAB%29+co-operative+group&amp;rft.au=Bennett+JM%2C+Catovsky+D%2C+Daniel+MT&amp;rft.aulast=Bennett+JM%2C+Catovsky+D%2C+Daniel+MT&amp;rft.date=August+1976&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1111%2Fj.1365-2141.1976.tb03563.x&amp;rft_id=info%3Apmid%2F188440&amp;rft.issue=4&amp;rft.jtitle=Br.+J.+Haematol.&amp;rft.pages=451-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=33" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-urlTable_1:_French-American-British_.28FAB.29_Classification_of_MDS-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-urlTable_1:_French-American-British_.28FAB.29_Classification_of_MDS_4-0">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.clevelandclinicmeded.com/diseasemanagement/hematology/myelo/table1.htm">"Table 1: French-American-British (FAB) Classification of MDS"</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.btitle=Table+1%3A+French-American-British+%28FAB%29+Classification+of+MDS&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.clevelandclinicmeded.com%2Fdiseasemanagement%2Fhematology%2Fmyelo%2Ftable1.htm&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-5">^</a></b></span> <span class="reference-text"><span class="citation journal">Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J (1997). "International scoring system for evaluating prognosis in myelodysplastic syndromes". <i>Blood</i> <b>89</b> (6): 2079–88. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/9058730">9058730</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=International+scoring+system+for+evaluating+prognosis+in+myelodysplastic+syndromes&amp;rft.au=Greenberg+P%2C+Cox+C%2C+LeBeau+MM%2C+Fenaux+P%2C+Morel+P%2C+Sanz+G%2C+Sanz+M%2C+Vallespi+T%2C+Hamblin+T%2C+Oscier+D%2C+Ohyashiki+K%2C+Toyama+K%2C+Aul+C%2C+Mufti+G%2C+Bennett+J&amp;rft.aulast=Greenberg+P%2C+Cox+C%2C+LeBeau+MM%2C+Fenaux+P%2C+Morel+P%2C+Sanz+G%2C+Sanz+M%2C+Vallespi+T%2C+Hamblin+T%2C+Oscier+D%2C+Ohyashiki+K%2C+Toyama+K%2C+Aul+C%2C+Mufti+G%2C+Bennett+J&amp;rft.date=1997&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F9058730&amp;rft.issue=6&amp;rft.jtitle=Blood&amp;rft.pages=2079-88&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=89" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text">Myelodysplastic Syndrome. The Leukemia &amp; Lymphoma Society. White Plains, NY. 2001. p 24. Retrieved 05-12-2008.</span></li>
<li id="cite_note-pmid12406866-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid12406866_7-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Cazzola M, Invernizzi R, Bergamaschi G et al. (2003). "Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia". <i>Blood</i> <b>101</b> (5): 1996–2000. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2002-07-2006">10.1182/blood-2002-07-2006</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12406866">12406866</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Mitochondrial+ferritin+expression+in+erythroid+cells+from+patients+with+sideroblastic+anemia&amp;rft.au=Cazzola+M%2C+Invernizzi+R%2C+Bergamaschi+G&amp;rft.aulast=Cazzola+M%2C+Invernizzi+R%2C+Bergamaschi+G&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2002-07-2006&amp;rft_id=info%3Apmid%2F12406866&amp;rft.issue=5&amp;rft.jtitle=Blood&amp;rft.pages=1996-2000&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=101" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid3552346-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid3552346_8-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Bunn HF (1986). "5q- and disordered haematopoiesis". <i>Clinics in haematology</i> <b>15</b> (4): 1023–35. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/3552346">3552346</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=5q-+and+disordered+haematopoiesis&amp;rft.au=Bunn+HF&amp;rft.aulast=Bunn+HF&amp;rft.date=1986&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F3552346&amp;rft.issue=4&amp;rft.jtitle=Clinics+in+haematology&amp;rft.pages=1023-35&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=15" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid4421285-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid4421285_9-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G (1974). "Distinct haematological disorder with deletion of long arm of no. 5 chromosome". <i>Nature</i> <b>251</b> (5474): 437–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1038%2F251437a0">10.1038/251437a0</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/4421285">4421285</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Distinct+haematological+disorder+with+deletion+of+long+arm+of+no.+5+chromosome&amp;rft.aulast=Van+den+Berghe+H%2C+Cassiman+JJ%2C+David+G%2C+Fryns+JP%2C+Michaux+JL%2C+Sokal+G&amp;rft.au=Van+den+Berghe+H%2C+Cassiman+JJ%2C+David+G%2C+Fryns+JP%2C+Michaux+JL%2C+Sokal+G&amp;rft.date=1974&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1038%2F251437a0&amp;rft_id=info%3Apmid%2F4421285&amp;rft.issue=5474&amp;rft.jtitle=Nature&amp;rft.pages=437-8&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=251" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid15703420-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid15703420_10-0">^</a></b></span> <span class="reference-text"><span class="citation journal">List A, Kurtin S, Roe DJ et al. (2005). "Efficacy of lenalidomide in myelodysplastic syndromes". <i>N. Engl. J. Med.</i> <b>352</b> (6): 549–57. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJMoa041668">10.1056/NEJMoa041668</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15703420">15703420</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Efficacy+of+lenalidomide+in+myelodysplastic+syndromes&amp;rft.aulast=List+A%2C+Kurtin+S%2C+Roe+DJ&amp;rft.au=List+A%2C+Kurtin+S%2C+Roe+DJ&amp;rft.date=2005&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa041668&amp;rft_id=info%3Apmid%2F15703420&amp;rft.issue=6&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=549-57&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=352" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-Rozovski2012-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-Rozovski2012_11-0">^</a></b></span> <span class="reference-text">Rozovski U, Keating M, Estrov Z (2012) The significance of spliceosome mutations in chronic lymphocytic leukemia. Leuk Lymphoma</span></li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text">Gondek LP, Tiu R, O'Keefe CL, Sekeres MA, Theil KS, Maciejewski JP. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008 Feb 1;111(3):1534-42.</span></li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="http://onlinelibrary.wiley.com/doi/10.1002/ajh.20864/pdf">http://onlinelibrary.wiley.com/doi/10.1002/ajh.20864/pdf</a></span></li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external text" href="http://www.marrowforums.org/mds.html">MDS - Myelodysplastic Syndromes</a></span></li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><span class="citation journal">Cutler CS, Lee SJ, Greenberg P, Deeg HJ, Perez WS, Anasetti C, Bolwell BJ, Cairo MS, Gale RP, Klein JP, Lazarus HM, Liesveld JL, McCarthy PL, Milone GA, Rizzo JD, Schultz KR, Trigg ME, Keating A, Weisdorf DJ, Antin JH, Horowitz MM (2004). "A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.". <i>Blood</i> <b>104</b> (2): 579–85. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2004-01-0338">10.1182/blood-2004-01-0338</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/15039286">15039286</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=A+decision+analysis+of+allogeneic+bone+marrow+transplantation+for+the+myelodysplastic+syndromes%3A+delayed+transplantation+for+low-risk+myelodysplasia+is+associated+with+improved+outcome.&amp;rft.au=Cutler+CS%2C+Lee+SJ%2C+Greenberg+P%2C+Deeg+HJ%2C+Perez+WS%2C+Anasetti+C%2C+Bolwell+BJ%2C+Cairo+MS%2C+Gale+RP%2C+Klein+JP%2C+Lazarus+HM%2C+Liesveld+JL%2C+McCarthy+PL%2C+Milone+GA%2C+Rizzo+JD%2C+Schultz+KR%2C+Trigg+ME%2C+Keating+A%2C+Weisdorf+DJ%2C+Antin+JH%2C+Horowitz+MM&amp;rft.aulast=Cutler+CS%2C+Lee+SJ%2C+Greenberg+P%2C+Deeg+HJ%2C+Perez+WS%2C+Anasetti+C%2C+Bolwell+BJ%2C+Cairo+MS%2C+Gale+RP%2C+Klein+JP%2C+Lazarus+HM%2C+Liesveld+JL%2C+McCarthy+PL%2C+Milone+GA%2C+Rizzo+JD%2C+Schultz+KR%2C+Trigg+ME%2C+Keating+A%2C+Weisdorf+DJ%2C+Antin+JH%2C+Horowitz+MM&amp;rft.date=2004&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2004-01-0338&amp;rft_id=info%3Apmid%2F15039286&amp;rft.issue=2&amp;rft.jtitle=Blood&amp;rft.pages=579-85&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=104" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text"><span class="citation web"><a rel="nofollow" class="external text" href="http://www.cms.hhs.gov/mcd/viewdecisionmemo.asp?id=203">"Centers for Medicare &amp; Medicaid Services"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">2007-10-29</span></span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.btitle=Centers+for+Medicare+%26+Medicaid+Services&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.cms.hhs.gov%2Fmcd%2Fviewdecisionmemo.asp%3Fid%3D203&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-pmid10694544-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid10694544_17-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Wijermans P, Lübbert M, Verhoef G et al. (2000). "Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients". <i>J. Clin. Oncol.</i> <b>18</b> (5): 956–62. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10694544">10694544</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Low-dose+5-aza-2%27-deoxycytidine%2C+a+DNA+hypomethylating+agent%2C+for+the+treatment+of+high-risk+myelodysplastic+syndrome%3A+a+multicenter+phase+II+study+in+elderly+patients&amp;rft.aulast=Wijermans+P%2C+L%C3%BCbbert+M%2C+Verhoef+G&amp;rft.au=Wijermans+P%2C+L%C3%BCbbert+M%2C+Verhoef+G&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F10694544&amp;rft.issue=5&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=956-62&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=18" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid11529854-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11529854_18-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Lübbert M, Wijermans P, Kunzmann R et al. (2001). "Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine". <i>Br. J. Haematol.</i> <b>114</b> (2): 349–57. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1046%2Fj.1365-2141.2001.02933.x">10.1046/j.1365-2141.2001.02933.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11529854">11529854</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Cytogenetic+responses+in+high-risk+myelodysplastic+syndrome+following+low-dose+treatment+with+the+DNA+methylation+inhibitor+5-aza-2%27-deoxycytidine&amp;rft.aulast=L%C3%BCbbert+M%2C+Wijermans+P%2C+Kunzmann+R&amp;rft.au=L%C3%BCbbert+M%2C+Wijermans+P%2C+Kunzmann+R&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1046%2Fj.1365-2141.2001.02933.x&amp;rft_id=info%3Apmid%2F11529854&amp;rft.issue=2&amp;rft.jtitle=Br.+J.+Haematol.&amp;rft.pages=349-57&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=114" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid12011120-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid12011120_19-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Silverman LR, Demakos EP, Peterson BL et al. (2002). "Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B". <i>J. Clin. Oncol.</i> <b>20</b> (10): 2429–40. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1200%2FJCO.2002.04.117">10.1200/JCO.2002.04.117</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/12011120">12011120</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Randomized+controlled+trial+of+azacitidine+in+patients+with+the+myelodysplastic+syndrome%3A+a+study+of+the+cancer+and+leukemia+group+B&amp;rft.aulast=Silverman+LR%2C+Demakos+EP%2C+Peterson+BL&amp;rft.au=Silverman+LR%2C+Demakos+EP%2C+Peterson+BL&amp;rft.date=2002&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2002.04.117&amp;rft_id=info%3Apmid%2F12011120&amp;rft.issue=10&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=2429-40&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=20" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid16921040-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16921040_20-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Silverman LR, McKenzie DR, Peterson BL et al. (2006). "Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B". <i>J. Clin. Oncol.</i> <b>24</b> (24): 3895–903. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1200%2FJCO.2005.05.4346">10.1200/JCO.2005.05.4346</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16921040">16921040</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Further+analysis+of+trials+with+azacitidine+in+patients+with+myelodysplastic+syndrome%3A+studies+8421%2C+8921%2C+and+9221+by+the+Cancer+and+Leukemia+Group+B&amp;rft.aulast=Silverman+LR%2C+McKenzie+DR%2C+Peterson+BL&amp;rft.au=Silverman+LR%2C+McKenzie+DR%2C+Peterson+BL&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2005.05.4346&amp;rft_id=info%3Apmid%2F16921040&amp;rft.issue=24&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=3895-903&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=24" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid17133405-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17133405_21-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Kantarjian HM, O'Brien S, Shan J et al. (2007). "Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome". <i>Cancer</i> <b>109</b> (2): 265–73. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2Fcncr.22376">10.1002/cncr.22376</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17133405">17133405</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Update+of+the+decitabine+experience+in+higher+risk+myelodysplastic+syndrome+and+analysis+of+prognostic+factors+associated+with+outcome&amp;rft.au=Kantarjian+HM%2C+O%27Brien+S%2C+Shan+J&amp;rft.aulast=Kantarjian+HM%2C+O%27Brien+S%2C+Shan+J&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fcncr.22376&amp;rft_id=info%3Apmid%2F17133405&amp;rft.issue=2&amp;rft.jtitle=Cancer&amp;rft.pages=265-73&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=109" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid16532500-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16532500_22-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Kantarjian H, Issa JP, Rosenfeld CS et al. (2006). "Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study". <i>Cancer</i> <b>106</b> (8): 1794–803. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1002%2Fcncr.21792">10.1002/cncr.21792</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16532500">16532500</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Decitabine+improves+patient+outcomes+in+myelodysplastic+syndromes%3A+results+of+a+phase+III+randomized+study&amp;rft.au=Kantarjian+H%2C+Issa+JP%2C+Rosenfeld+CS&amp;rft.aulast=Kantarjian+H%2C+Issa+JP%2C+Rosenfeld+CS&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1002%2Fcncr.21792&amp;rft_id=info%3Apmid%2F16532500&amp;rft.issue=8&amp;rft.jtitle=Cancer&amp;rft.pages=1794-803&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=106" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid16882708-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16882708_23-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Kantarjian H, Oki Y, Garcia-Manero G et al. (2007). "Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia". <i>Blood</i> <b>109</b> (1): 52–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1182%2Fblood-2006-05-021162">10.1182/blood-2006-05-021162</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16882708">16882708</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Results+of+a+randomized+study+of+3+schedules+of+low-dose+decitabine+in+higher-risk+myelodysplastic+syndrome+and+chronic+myelomonocytic+leukemia&amp;rft.au=Kantarjian+H%2C+Oki+Y%2C+Garcia-Manero+G&amp;rft.aulast=Kantarjian+H%2C+Oki+Y%2C+Garcia-Manero+G&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1182%2Fblood-2006-05-021162&amp;rft_id=info%3Apmid%2F16882708&amp;rft.issue=1&amp;rft.jtitle=Blood&amp;rft.pages=52-7&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=109" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid17679729-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17679729_24-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Blum W, Klisovic RB, Hackanson B et al. (2007). "Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia". <i>J. Clin. Oncol.</i> <b>25</b> (25): 3884–91. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1200%2FJCO.2006.09.4169">10.1200/JCO.2006.09.4169</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17679729">17679729</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Phase+I+study+of+decitabine+alone+or+in+combination+with+valproic+acid+in+acute+myeloid+leukemia&amp;rft.au=Blum+W%2C+Klisovic+RB%2C+Hackanson+B&amp;rft.aulast=Blum+W%2C+Klisovic+RB%2C+Hackanson+B&amp;rft.date=2007&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1200%2FJCO.2006.09.4169&amp;rft_id=info%3Apmid%2F17679729&amp;rft.issue=25&amp;rft.jtitle=J.+Clin.+Oncol.&amp;rft.pages=3884-91&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=25" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid17021321-25"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid17021321_25-0">^</a></b></span> <span class="reference-text"><span class="citation journal">List A, Dewald G, Bennett J et al. (2006). "Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion". <i>N. Engl. J. Med.</i> <b>355</b> (14): 1456–65. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1056%2FNEJMoa061292">10.1056/NEJMoa061292</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/17021321">17021321</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Lenalidomide+in+the+myelodysplastic+syndrome+with+chromosome+5q+deletion&amp;rft.aulast=List+A%2C+Dewald+G%2C+Bennett+J&amp;rft.au=List+A%2C+Dewald+G%2C+Bennett+J&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1056%2FNEJMoa061292&amp;rft_id=info%3Apmid%2F17021321&amp;rft.issue=14&amp;rft.jtitle=N.+Engl.+J.+Med.&amp;rft.pages=1456-65&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=355" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid16625140-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid16625140_26-0">^</a></b></span> <span class="reference-text"><span class="citation journal">"Lenalidomide (Revlimid) for anemia of myelodysplastic syndrome". <i>The Medical letter on drugs and therapeutics</i> <b>48</b> (1232): 31–2. 2006. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/16625140">16625140</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Lenalidomide+%28Revlimid%29+for+anemia+of+myelodysplastic+syndrome&amp;rft.date=2006&amp;rft.genre=article&amp;rft_id=info%3Apmid%2F16625140&amp;rft.issue=1232&amp;rft.jtitle=The+Medical+letter+on+drugs+and+therapeutics&amp;rft.pages=31-2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=48" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><span class="citation journal">Oosterveld M, Wittebol S, Lemmens W, Kiemeney B, Catik A, Muus P, Schattenberg A, de Witte T (2003). "The impact of intensive antileukaemic treatment strategies on prognosis of myelodysplastic syndrome patients aged less than 61 years according to International Prognostic Scoring System risk groups". <i>Br J Haematol</i> <b>123</b> (1): 81–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1046%2Fj.1365-2141.2003.04544.x">10.1046/j.1365-2141.2003.04544.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/14510946">14510946</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=The+impact+of+intensive+antileukaemic+treatment+strategies+on+prognosis+of+myelodysplastic+syndrome+patients+aged+less+than+61+years+according+to+International+Prognostic+Scoring+System+risk+groups&amp;rft.aulast=Oosterveld+M%2C+Wittebol+S%2C+Lemmens+W%2C+Kiemeney+B%2C+Catik+A%2C+Muus+P%2C+Schattenberg+A%2C+de+Witte+T&amp;rft.au=Oosterveld+M%2C+Wittebol+S%2C+Lemmens+W%2C+Kiemeney+B%2C+Catik+A%2C+Muus+P%2C+Schattenberg+A%2C+de+Witte+T&amp;rft.date=2003&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1046%2Fj.1365-2141.2003.04544.x&amp;rft_id=info%3Apmid%2F14510946&amp;rft.issue=1&amp;rft.jtitle=Br+J+Haematol&amp;rft.pages=81-9&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=123" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="http://www.clinicaltrials.gov/">http://www.clinicaltrials.gov/</a></span></li>
<li id="cite_note-Harrison.27s-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-Harrison.27s_29-0">^</a></b></span> <span class="reference-text"><span class="citation book">Kasper, Dennis L; Braunwald, Eugene; Fauci, Anthony; et al. (2005). <i>Harrison's Principles of Internal Medicine</i> (16th ed.). New York: McGraw-Hill. p.&#160;625. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a>&#160;<a href="/wiki/Special:BookSources/0-07-139140-1" title="Special:BookSources/0-07-139140-1">0-07-139140-1</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.au=Kasper%2C+Dennis+L%3B+Braunwald%2C+Eugene%3B+Fauci%2C+Anthony%3B&amp;rft.aulast=Kasper%2C+Dennis+L%3B+Braunwald%2C+Eugene%3B+Fauci%2C+Anthony%3B&amp;rft.btitle=Harrison%27s+Principles+of+Internal+Medicine&amp;rft.date=2005&amp;rft.edition=16th&amp;rft.genre=book&amp;rft.isbn=0-07-139140-1&amp;rft.pages=625&amp;rft.place=New+York&amp;rft.pub=McGraw-Hill&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid10691865-30"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid10691865_30-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Solé E et al. (2000). "Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes". <i>British Journal of Haematology</i> <b>108</b> (2): 346–356. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1046%2Fj.1365-2141.2000.01868.x">10.1046/j.1365-2141.2000.01868.x</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/10691865">10691865</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Incidence%2C+characterization+and+prognostic+significance+of+chromosomal+abnormalities+in+640+patients+with+primary+myelodysplastic+syndromes&amp;rft.aulast=Sol%C3%A9+E&amp;rft.au=Sol%C3%A9+E&amp;rft.date=2000&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1046%2Fj.1365-2141.2000.01868.x&amp;rft_id=info%3Apmid%2F10691865&amp;rft.issue=2&amp;rft.jtitle=British+Journal+of+Haematology&amp;rft.pages=346-356&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=108" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><span class="citation journal">Greenberg et al. (1997). "International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes". <i>Blood</i> <b>89</b>: 2079–2088.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=International+Scoring+System+for+Evaluating+Prognosis+in+Myelodysplastic+Syndromes&amp;rft.au=Greenberg&amp;rft.aulast=Greenberg&amp;rft.date=1997&amp;rft.genre=article&amp;rft.jtitle=Blood&amp;rft.pages=2079-2088&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=89" class="Z3988"><span style="display:none;">&#160;</span></span> <span class="citation-comment" style="display:none; color:#33aa33">CS1 maint: Explicit use of et al. (<a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">link</a>)</span></span></li>
<li id="cite_note-pmid11503953-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-pmid11503953_32-0">^</a></b></span> <span class="reference-text"><span class="citation journal">Aul C, Giagounidis A, Germing U (2001). "Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics". <i>Int. J. Hematol.</i> <b>73</b> (4): 405–10. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1007%2FBF02994001">10.1007/BF02994001</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/11503953">11503953</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Epidemiological+features+of+myelodysplastic+syndromes%3A+results+from+regional+cancer+surveys+and+hospital-based+statistics&amp;rft.au=Aul+C%2C+Giagounidis+A%2C+Germing+U&amp;rft.aulast=Aul+C%2C+Giagounidis+A%2C+Germing+U&amp;rft.date=2001&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1007%2FBF02994001&amp;rft_id=info%3Apmid%2F11503953&amp;rft.issue=4&amp;rft.jtitle=Int.+J.+Hematol.&amp;rft.pages=405-10&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=73" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><span class="citation journal">Block M, Jacobson LO, Bethard WF (July 1953). "Preleukemic acute human leukemia". <i>J Am Med Assoc</i> <b>152</b> (11): 1018–28. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="//dx.doi.org/10.1001%2Fjama.1953.03690110032010">10.1001/jama.1953.03690110032010</a>. <a href="/wiki/PubMed_Identifier" title="PubMed Identifier" class="mw-redirect">PMID</a>&#160;<a rel="nofollow" class="external text" href="//www.ncbi.nlm.nih.gov/pubmed/13052490">13052490</a>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.atitle=Preleukemic+acute+human+leukemia&amp;rft.au=Block+M%2C+Jacobson+LO%2C+Bethard+WF&amp;rft.aulast=Block+M%2C+Jacobson+LO%2C+Bethard+WF&amp;rft.date=July+1953&amp;rft.genre=article&amp;rft_id=info%3Adoi%2F10.1001%2Fjama.1953.03690110032010&amp;rft_id=info%3Apmid%2F13052490&amp;rft.issue=11&amp;rft.jtitle=J+Am+Med+Assoc&amp;rft.pages=1018-28&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.volume=152" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><span class="citation web">Hewitt, Ed (25 June 2013). <a rel="nofollow" class="external text" href="http://www.row2k.com/features/744/Harry-Parker-has-passed--a-remembrance--1935-2013/#.UcyjzuD-hdZ">"Harry Parker has passed; a remembrance, 1935-2013"</a>. Row2k<span class="reference-accessdate">. Retrieved <span class="nowrap">27 June</span> 2013</span>.</span><span title="ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMyelodysplastic+syndrome&amp;rft.aufirst=Ed&amp;rft.au=Hewitt%2C+Ed&amp;rft.aulast=Hewitt&amp;rft.btitle=Harry+Parker+has+passed%3B+a+remembrance%2C+1935-2013&amp;rft.date=25+June+2013&amp;rft.genre=book&amp;rft_id=http%3A%2F%2Fwww.row2k.com%2Ffeatures%2F744%2FHarry-Parker-has-passed--a-remembrance--1935-2013%2F%23.UcyjzuD-hdZ&amp;rft.pub=Row2k&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook" class="Z3988"><span style="display:none;">&#160;</span></span></span></li>
</ol>
</div>
<h2><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=17" title="Edit section: External links">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<table class="mbox-small plainlinks sistersitebox" style="border:1px solid #aaa;background-color:#f9f9f9">
<tr>
<td class="mbox-image"><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/30px-Commons-logo.svg.png" width="30" height="40" srcset="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/45px-Commons-logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/59px-Commons-logo.svg.png 2x" data-file-width="1024" data-file-height="1376" /></td>
<td class="mbox-text plainlist">Wikimedia Commons has media related to <i><b><a href="//commons.wikimedia.org/wiki/Category:Myelodysplastic_syndrome" class="extiw" title="commons:Category:Myelodysplastic syndrome">Myelodysplastic syndrome</a></b></i>.</td>
</tr>
</table>
<ul>
<li><a rel="nofollow" class="external autonumber" href="http://www.aamds.org/aplastic/disease_information/myelodysplastic_synd/">[1]</a> Aplastic Anemia &amp; MDS International Foundation] information about MDS</li>
<li>"MDS Explained," Parts <a rel="nofollow" class="external text" href="http://www.youtube.com/watch?v=fPye7q6Nt6w&amp;feature=channel">1</a>, <a rel="nofollow" class="external text" href="http://www.youtube.com/watch?v=AlNpsjzD44o&amp;feature=channel">2</a>, and <a rel="nofollow" class="external text" href="http://www.youtube.com/watch?v=BVzGou1kpdw&amp;feature=channel">3</a> (video presentations)</li>
<li><a rel="nofollow" class="external text" href="http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/hematology-oncology/chronic-myeloproliferative-disorders/">Chronic Myeloproliferative Disorders</a>. Comprehensive chapter from Cleveland Clinic</li>
<li>Iwanaga, Masako, et al. 2010. <i><a rel="nofollow" class="external text" href="http://jco.ascopubs.org/content/29/4/428.full">Risk of Myelodysplastic Syndromes in People Exposed to Ionizing Radiation: A Retrospective Cohort Study of Nagasaki Atomic Bomb Survivors</a></i>. American Society of Clinical Oncology.</li>
<li>What Can I Do? <i><a rel="nofollow" class="external autonumber" href="http://www.lowbloodcounts.com/sv/what-should-i-do/">[2]</a></i>. lowbloodcounts.com.</li>
</ul>
<h2><span class="mw-headline" id="See_also">See also</span><span class="mw-editsection"><span class="mw-editsection-bracket">[</span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit&amp;section=18" title="Edit section: See also">edit</a><span class="mw-editsection-bracket">]</span></span></h2>
<ul>
<li><a href="/wiki/Myeloproliferative_syndrome" title="Myeloproliferative syndrome" class="mw-redirect">Myeloproliferative syndrome</a></li>
<li><a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">Acute myeloid leukemia</a></li>
<li><a href="/wiki/Chloroma" title="Chloroma" class="mw-redirect">Chloroma</a></li>
</ul>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks collapsible autocollapse navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Myeloid_malignancy" title="Template:Myeloid malignancy"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Myeloid_malignancy" title="Template talk:Myeloid malignancy"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Myeloid_malignancy&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%"><a href="/wiki/Myeloid" title="Myeloid">Myeloid</a> <a href="/wiki/Hematological_malignancy" title="Hematological malignancy" class="mw-redirect">hematological malignancy</a>/<a href="/wiki/Leukemia" title="Leukemia">leukemia</a> histology (<a href="/wiki/International_Classification_of_Diseases_for_Oncology" title="International Classification of Diseases for Oncology">ICD-O</a> 9590–9989, <a href="/wiki/ICD-10_Chapter_II:_Neoplasms#.28C81.E2.80.93C96.29_Malignant_neoplasms.2C_stated_or_presumed_to_be_primary.2C_of_lymphoid.2C_haematopoietic_and_related_tissue" title="ICD-10 Chapter II: Neoplasms">C81–C96</a>, <a href="/wiki/List_of_ICD-9_codes_140%E2%80%93239:_neoplasms#Malignant_neoplasm_of_lymphatic_and_hematopoietic_tissue_.28200.E2.80.93208.29" title="List of ICD-9 codes 140–239: neoplasms">200–208</a>)</div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-GM" title="CFU-GM">CFU-GM</a>/<br />
and other <a href="/wiki/Granulocyte" title="Granulocyte">granulocytes</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-GM" title="CFU-GM">CFU-GM</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Myelocyte" title="Myelocyte">Myelocyte</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">AML</a>:</i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_myeloblastic_leukemia" title="Acute myeloblastic leukemia">Acute myeloblastic leukemia</a></li>
<li><a href="/wiki/Minimally_differentiated_acute_myeloblastic_leukemia" title="Minimally differentiated acute myeloblastic leukemia">M0</a></li>
<li><a href="/wiki/Acute_myeloblastic_leukemia_without_maturation" title="Acute myeloblastic leukemia without maturation">M1</a></li>
<li><a href="/wiki/Acute_myeloblastic_leukemia_with_maturation" title="Acute myeloblastic leukemia with maturation">M2</a></li>
<li><a href="/wiki/Acute_promyelocytic_leukemia" title="Acute promyelocytic leukemia">APL/M3</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Chronic_neutrophilic_leukemia" title="Chronic neutrophilic leukemia">Chronic neutrophilic leukemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Monocyte" title="Monocyte">Monocyte</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">AML</a></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_monocytic_leukemia" title="Acute monocytic leukemia">AMoL/M5</a></li>
<li><a href="/wiki/Acute_myeloid_dendritic_cell_leukemia" title="Acute myeloid dendritic cell leukemia">Myeloid dendritic cell leukemia</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Chronic_myelogenous_leukemia" title="Chronic myelogenous leukemia">CML</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Philadelphia_chromosome" title="Philadelphia chromosome">Philadelphia chromosome</a></li>
<li><a href="/wiki/Accelerated_phase_chronic_myelogenous_leukemia" title="Accelerated phase chronic myelogenous leukemia">Accelerated phase chronic myelogenous leukemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Myelomonocyte" title="Myelomonocyte">Myelomonocyte</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">AML</a></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_myelomonocytic_leukemia" title="Acute myelomonocytic leukemia">M4</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myelodysplastic%E2%80%93myeloproliferative_diseases" title="Myelodysplastic–myeloproliferative diseases">MD-MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Juvenile_myelomonocytic_leukemia" title="Juvenile myelomonocytic leukemia">Juvenile myelomonocytic leukemia</a></li>
<li><a href="/wiki/Chronic_myelomonocytic_leukemia" title="Chronic myelomonocytic leukemia">Chronic myelomonocytic leukemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Other</th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Histiocytosis" title="Histiocytosis">Histiocytosis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-Baso" title="CFU-Baso">CFU-Baso</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">AML</a></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_basophilic_leukemia" title="Acute basophilic leukemia">Acute basophilic</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-Eos" title="CFU-Eos">CFU-Eos</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">AML</a></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_eosinophilic_leukemia" title="Acute eosinophilic leukemia">Acute eosinophilic</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Chronic_eosinophilic_leukemia" title="Chronic eosinophilic leukemia">Chronic eosinophilic leukemia</a>/<a href="/wiki/Hypereosinophilic_syndrome" title="Hypereosinophilic syndrome">Hypereosinophilic syndrome</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Megakaryocyte%E2%80%93erythroid_progenitor_cell" title="Megakaryocyte–erythroid progenitor cell">MEP</a></th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-Meg" title="CFU-Meg">CFU-Meg</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">AML</a></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_megakaryoblastic_leukemia" title="Acute megakaryoblastic leukemia">AMKL/M7</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Essential_thrombocytosis" title="Essential thrombocytosis" class="mw-redirect">Essential thrombocytosis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-E" title="CFU-E">CFU-E</a></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">AML</a></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_erythroid_leukemia" title="Acute erythroid leukemia">Erythroleukemia/M6</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Polycythemia_vera" title="Polycythemia vera">Polycythemia vera</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><strong class="selflink">MD</strong></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Anemia" title="Anemia">Refractory anemia</a></li>
<li><a href="/wiki/Refractory_anemia_with_excess_of_blasts" title="Refractory anemia with excess of blasts">Refractory anemia with excess of blasts</a></li>
<li><a href="/wiki/Chromosome_5q_deletion_syndrome" title="Chromosome 5q deletion syndrome">Chromosome 5q deletion syndrome</a></li>
<li><a href="/wiki/Sideroblastic_anemia" title="Sideroblastic anemia">Sideroblastic anemia</a></li>
<li><a href="/wiki/Paroxysmal_nocturnal_hemoglobinuria" title="Paroxysmal nocturnal hemoglobinuria">Paroxysmal nocturnal hemoglobinuria</a></li>
<li><a href="/wiki/Refractory_cytopenia_with_multilineage_dysplasia" title="Refractory cytopenia with multilineage dysplasia">Refractory cytopenia with multilineage dysplasia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/CFU-Mast" title="CFU-Mast">CFU-Mast</a></th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Mastocytoma" title="Mastocytoma">Mastocytoma</a></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Mast_cell_leukemia" title="Mast cell leukemia">Mast cell leukemia</a></li>
<li><a href="/wiki/Mast_cell_sarcoma" title="Mast cell sarcoma">Mast cell sarcoma</a></li>
<li><a href="/wiki/Mastocytosis" title="Mastocytosis">Systemic mastocytosis</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><a href="/wiki/Mastocytosis" title="Mastocytosis">Mastocytosis</a>:</span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Diffuse_cutaneous_mastocytosis" title="Diffuse cutaneous mastocytosis">Diffuse cutaneous mastocytosis</a></li>
<li><a href="/wiki/Erythrodermic_mastocytosis" title="Erythrodermic mastocytosis">Erythrodermic mastocytosis</a></li>
<li><a href="/wiki/Adult_type_of_generalized_eruption_of_cutaneous_mastocytosis" title="Adult type of generalized eruption of cutaneous mastocytosis">Adult type of generalized eruption of cutaneous mastocytosis</a></li>
<li><a href="/wiki/Urticaria_pigmentosa" title="Urticaria pigmentosa">Urticaria pigmentosa</a></li>
<li><a href="/wiki/Mast_cell_sarcoma" title="Mast cell sarcoma">Mast cell sarcoma</a></li>
<li><a href="/wiki/Solitary_mastocytoma" title="Solitary mastocytoma">Solitary mastocytoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;">Systemic mastocytosis</span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Xanthelasmoidal_mastocytosis" title="Xanthelasmoidal mastocytosis">Xanthelasmoidal mastocytosis</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Multiple/unknown</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em"></div>
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Acute_myeloid_leukemia" title="Acute myeloid leukemia">AML</a></i></span></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Acute_panmyelosis_with_myelofibrosis" title="Acute panmyelosis with myelofibrosis">Acute panmyelosis with myelofibrosis</a></li>
<li><a href="/wiki/Myeloid_sarcoma" title="Myeloid sarcoma">Myeloid sarcoma</a></li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group"><span style="font-weight:normal;"><i><a href="/wiki/Myeloproliferative_disease" title="Myeloproliferative disease" class="mw-redirect">MP</a></i></span></th>
<td class="navbox-list navbox-even" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Myelofibrosis" title="Myelofibrosis">Myelofibrosis</a></li>
<li><a href="/wiki/Acute_biphenotypic_leukaemia" title="Acute biphenotypic leukaemia">Acute biphenotypic leukaemia</a></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<td class="navbox-abovebelow" colspan="2" style="background: transparent; padding: 0px;">
<table class="nowraplinks navbox-subgroup" style="border-spacing:0">
<tr>
<th scope="col" class="navbox-title" colspan="2">
<div class="plainlinks hlist navbar mini">
<ul>
<li class="nv-view"><a href="/wiki/Template:Myeloid_navs" title="Template:Myeloid navs"><span title="View this template" style=";;background:none transparent;border:none;">v</span></a></li>
<li class="nv-talk"><a href="/wiki/Template_talk:Myeloid_navs" title="Template talk:Myeloid navs"><span title="Discuss this template" style=";;background:none transparent;border:none;">t</span></a></li>
<li class="nv-edit"><a class="external text" href="//en.wikipedia.org/w/index.php?title=Template:Myeloid_navs&amp;action=edit"><span title="Edit this template" style=";;background:none transparent;border:none;">e</span></a></li>
</ul>
</div>
<div style="font-size:110%">Index of <a href="/wiki/Myeloid" title="Myeloid">cells from bone marrow</a></div>
</th>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Description</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Myeloid_innate_immune_system" title="Template:Myeloid innate immune system">Immune system</a></li>
<li><a href="/wiki/Template:Myeloid_blood_cells_and_plasma" title="Template:Myeloid blood cells and plasma">Cells</a></li>
<li><a href="/wiki/Template:Myeloid_physiology" title="Template:Myeloid physiology">Physiology</a>
<ul>
<li><a href="/wiki/Template:Coagulation" title="Template:Coagulation">coagulation</a></li>
<li><a href="/wiki/Template:Hemeproteins" title="Template:Hemeproteins">proteins</a></li>
<li><a href="/wiki/Template:Granule_contents" title="Template:Granule contents">granule contents</a></li>
<li><a href="/wiki/Template:Colony-stimulating_factors" title="Template:Colony-stimulating factors">colony-stimulating</a></li>
<li>heme and porphyrin
<ul>
<li><i><a href="/wiki/Template:Porphyrin_metabolism_enzymes" title="Template:Porphyrin metabolism enzymes">metabolism</a></i></li>
<li><i><a href="/wiki/Template:Heme_metabolism_intermediates" title="Template:Heme metabolism intermediates">intermediates</a></i></li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Disease</th>
<td class="navbox-list navbox-even hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Diseases_of_RBCs_and_megakaryocytes" title="Template:Diseases of RBCs and megakaryocytes">Red blood cell</a></li>
<li><a href="/wiki/Template:Monocyte_and_granulocyte_disease" title="Template:Monocyte and granulocyte disease">Monocyte and granulocyte</a></li>
<li><a href="/wiki/Template:Myeloid_malignancy" title="Template:Myeloid malignancy">Neoplasms and cancer</a></li>
<li><a href="/wiki/Template:Histiocytosis" title="Template:Histiocytosis">Histiocytosis</a></li>
<li><a href="/wiki/Template:Cardiovascular_system_symptoms_and_signs" title="Template:Cardiovascular system symptoms and signs">Symptoms and signs</a>
<ul>
<li><a href="/wiki/Template:Eponymous_medical_signs_for_hematology" title="Template:Eponymous medical signs for hematology">eponymous</a></li>
</ul>
</li>
<li><a href="/wiki/Template:Myeloid_blood_tests" title="Template:Myeloid blood tests">Blood tests</a>
<ul>
<li><a href="/wiki/Template:Abnormal_clinical_and_laboratory_findings_for_blood" title="Template:Abnormal clinical and laboratory findings for blood">findings</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
<tr style="height:2px">
<td colspan="2"></td>
</tr>
<tr>
<th scope="row" class="navbox-group">Treatment</th>
<td class="navbox-list navbox-odd hlist" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Template:Transfusion_medicine" title="Template:Transfusion medicine">Transfusion</a></li>
<li>Drugs
<ul>
<li><a href="/wiki/Template:Antithrombotics" title="Template:Antithrombotics">thrombosis</a></li>
<li><a href="/wiki/Template:Antihemorrhagics" title="Template:Antihemorrhagics">bleeding</a></li>
<li><a href="/wiki/Template:B03,_B05,_B06" title="Template:B03, B05, B06">other</a></li>
</ul>
</li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table class="navbox" style="border-spacing:0">
<tr>
<td style="padding:2px">
<table class="nowraplinks hlist navbox-inner" style="border-spacing:0;background:transparent;color:inherit">
<tr>
<th scope="row" class="navbox-group"><a href="/wiki/Help:Authority_control" title="Help:Authority control">Authority control</a></th>
<td class="navbox-list navbox-odd" style="text-align:left;border-left-width:2px;border-left-style:solid;width:100%;padding:0px">
<div style="padding:0em 0.25em">
<ul>
<li><a href="/wiki/Integrated_Authority_File" title="Integrated Authority File">GND</a>: <span class="uid"><a rel="nofollow" class="external text" href="http://d-nb.info/gnd/4281183-1">4281183-1</a></span></li>
<li><a href="/wiki/National_Diet_Library" title="National Diet Library">NDL</a>: <span class="uid"><a rel="nofollow" class="external text" href="http://id.ndl.go.jp/auth/ndlna/01159248">01159248</a></span></li>
</ul>
</div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Parsed by mw1252
CPU time usage: 0.453 seconds
Real time usage: 0.552 seconds
Preprocessor visited node count: 2927/1000000
Preprocessor generated node count: 0/1500000
Post‐expand include size: 173522/2097152 bytes
Template argument size: 1999/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 1/500
Lua time usage: 0.161/10.000 seconds
Lua memory usage: 3.77 MB/50 MB
-->

<!-- 
Transclusion expansion time report (%,ms,calls,template)
100.00%  408.613      1 - -total
 36.34%  148.475     14 - Template:Navbox
 33.81%  138.148      1 - Template:Reflist
 20.17%   82.406      1 - Template:Infobox_disease
 18.57%   75.883     22 - Template:Cite_journal
 18.02%   73.636      1 - Template:Infobox
 17.42%   71.195      1 - Template:Myeloid_malignancy
 10.35%   42.277      1 - Template:Citation_needed
  8.50%   34.713      1 - Template:Fix
  7.42%   30.318      2 - Template:Category_handler
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:186367-0!*!0!!en!4!* and timestamp 20150712012028 and revision id 669828767
 -->
<noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div>					<div class="printfooter">
						Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Myelodysplastic_syndrome&amp;oldid=669828767">https://en.wikipedia.org/w/index.php?title=Myelodysplastic_syndrome&amp;oldid=669828767</a>"					</div>
				<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/wiki/Help:Category" title="Help:Category">Categories</a>: <ul><li><a href="/wiki/Category:Myeloid_neoplasia" title="Category:Myeloid neoplasia">Myeloid neoplasia</a></li><li><a href="/wiki/Category:Syndromes" title="Category:Syndromes">Syndromes</a></li></ul></div><div id="mw-hidden-catlinks" class="mw-hidden-catlinks mw-hidden-cats-hidden">Hidden categories: <ul><li><a href="/wiki/Category:CS1_maint:_Explicit_use_of_et_al." title="Category:CS1 maint: Explicit use of et al.">CS1 maint: Explicit use of et al.</a></li><li><a href="/wiki/Category:Articles_with_contributors_link" title="Category:Articles with contributors link">Articles with contributors link</a></li><li><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></li><li><a href="/wiki/Category:Articles_with_unsourced_statements_from_April_2011" title="Category:Articles with unsourced statements from April 2011">Articles with unsourced statements from April 2011</a></li><li><a href="/wiki/Category:Commons_category_with_local_link_same_as_on_Wikidata" title="Category:Commons category with local link same as on Wikidata">Commons category with local link same as on Wikidata</a></li><li><a href="/wiki/Category:Articles_that_use_a_Medicine_navs_subtemplate" title="Category:Articles that use a Medicine navs subtemplate">Articles that use a Medicine navs subtemplate</a></li><li><a href="/wiki/Category:Wikipedia_articles_with_GND_identifiers" title="Category:Wikipedia articles with GND identifiers">Wikipedia articles with GND identifiers</a></li></ul></div></div>				<div class="visualClear"></div>
							</div>
		</div>
		<div id="mw-navigation">
			<h2>Navigation menu</h2>

			<div id="mw-head">
									<div id="p-personal" role="navigation" class="" aria-labelledby="p-personal-label">
						<h3 id="p-personal-label">Personal tools</h3>
						<ul>
							<li id="pt-createaccount"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Myelodysplastic+syndrome&amp;type=signup" title="You are encouraged to create an account and log in; however, it is not mandatory">Create account</a></li><li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Myelodysplastic+syndrome" title="You're encouraged to log in; however, it's not mandatory. [o]" accesskey="o">Log in</a></li>						</ul>
					</div>
									<div id="left-navigation">
										<div id="p-namespaces" role="navigation" class="vectorTabs" aria-labelledby="p-namespaces-label">
						<h3 id="p-namespaces-label">Namespaces</h3>
						<ul>
															<li  id="ca-nstab-main" class="selected"><span><a href="/wiki/Myelodysplastic_syndrome"  title="View the content page [c]" accesskey="c">Article</a></span></li>
															<li  id="ca-talk"><span><a href="/wiki/Talk:Myelodysplastic_syndrome"  title="Discussion about the content page [t]" accesskey="t" rel="discussion">Talk</a></span></li>
													</ul>
					</div>
										<div id="p-variants" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-variants-label">
												<h3 id="p-variants-label">
							<span>Variants</span><a href="#"></a>
						</h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
									</div>
				<div id="right-navigation">
										<div id="p-views" role="navigation" class="vectorTabs" aria-labelledby="p-views-label">
						<h3 id="p-views-label">Views</h3>
						<ul>
															<li id="ca-view" class="selected"><span><a href="/wiki/Myelodysplastic_syndrome" >Read</a></span></li>
															<li id="ca-edit"><span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=edit"  title="Edit this page [e]" accesskey="e">Edit</a></span></li>
															<li id="ca-history" class="collapsible"><span><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=history"  title="Past versions of this page [h]" accesskey="h">View history</a></span></li>
													</ul>
					</div>
										<div id="p-cactions" role="navigation" class="vectorMenu emptyPortlet" aria-labelledby="p-cactions-label">
						<h3 id="p-cactions-label"><span>More</span><a href="#"></a></h3>

						<div class="menu">
							<ul>
															</ul>
						</div>
					</div>
										<div id="p-search" role="search">
						<h3>
							<label for="searchInput">Search</label>
						</h3>

						<form action="/w/index.php" id="searchform">
							<div id="simpleSearch">
							<input type="search" name="search" placeholder="Search" title="Search Wikipedia [f]" accesskey="f" id="searchInput" /><input type="hidden" value="Special:Search" name="title" /><input type="submit" name="fulltext" value="Search" title="Search Wikipedia for this text" id="mw-searchButton" class="searchButton mw-fallbackSearchButton" /><input type="submit" name="go" value="Go" title="Go to a page with this exact name if one exists" id="searchButton" class="searchButton" />							</div>
						</form>
					</div>
									</div>
			</div>
			<div id="mw-panel">
				<div id="p-logo" role="banner"><a class="mw-wiki-logo" href="/wiki/Main_Page"  title="Visit the main page"></a></div>
						<div class="portal" role="navigation" id='p-navigation' aria-labelledby='p-navigation-label'>
			<h3 id='p-navigation-label'>Navigation</h3>

			<div class="body">
									<ul>
						<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li><li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li><li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content – the best of Wikipedia">Featured content</a></li><li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li><li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li><li id="n-sitesupport"><a href="https://donate.wikimedia.org/wiki/Special:FundraiserRedirector?utm_source=donate&amp;utm_medium=sidebar&amp;utm_campaign=C13_en.wikipedia.org&amp;uselang=en" title="Support us">Donate to Wikipedia</a></li><li id="n-shoplink"><a href="//shop.wikimedia.org" title="Visit the Wikimedia Shop">Wikipedia store</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-interaction' aria-labelledby='p-interaction-label'>
			<h3 id='p-interaction-label'>Interaction</h3>

			<div class="body">
									<ul>
						<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li><li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li><li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li><li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="A list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li><li id="n-contactpage"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-tb' aria-labelledby='p-tb-label'>
			<h3 id='p-tb-label'>Tools</h3>

			<div class="body">
									<ul>
						<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Myelodysplastic_syndrome" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li><li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Myelodysplastic_syndrome" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li><li id="t-upload"><a href="/wiki/Wikipedia:File_Upload_Wizard" title="Upload files [u]" accesskey="u">Upload file</a></li><li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q">Special pages</a></li><li id="t-permalink"><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;oldid=669828767" title="Permanent link to this revision of the page">Permanent link</a></li><li id="t-info"><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;action=info" title="More information about this page">Page information</a></li><li id="t-wikibase"><a href="//www.wikidata.org/wiki/Q954625" title="Link to connected data repository item [g]" accesskey="g">Wikidata item</a></li><li id="t-cite"><a href="/w/index.php?title=Special:CiteThisPage&amp;page=Myelodysplastic_syndrome&amp;id=669828767" title="Information on how to cite this page">Cite this page</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-coll-print_export' aria-labelledby='p-coll-print_export-label'>
			<h3 id='p-coll-print_export-label'>Print/export</h3>

			<div class="body">
									<ul>
						<li id="coll-create_a_book"><a href="/w/index.php?title=Special:Book&amp;bookcmd=book_creator&amp;referer=Myelodysplastic+syndrome">Create a book</a></li><li id="coll-download-as-rdf2latex"><a href="/w/index.php?title=Special:Book&amp;bookcmd=render_article&amp;arttitle=Myelodysplastic+syndrome&amp;oldid=669828767&amp;writer=rdf2latex">Download as PDF</a></li><li id="t-print"><a href="/w/index.php?title=Myelodysplastic_syndrome&amp;printable=yes" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>					</ul>
							</div>
		</div>
			<div class="portal" role="navigation" id='p-lang' aria-labelledby='p-lang-label'>
			<h3 id='p-lang-label'>Languages</h3>

			<div class="body">
									<ul>
						<li class="interlanguage-link interwiki-ar"><a href="//ar.wikipedia.org/wiki/%D9%85%D8%AA%D9%84%D8%A7%D8%B2%D9%85%D8%A9_%D8%AE%D9%84%D9%84_%D8%A7%D9%84%D8%AA%D9%86%D8%B3%D8%AC_%D8%A7%D9%84%D9%86%D9%82%D9%88%D9%8A" title="متلازمة خلل التنسج النقوي – Arabic" lang="ar" hreflang="ar">العربية</a></li><li class="interlanguage-link interwiki-ca"><a href="//ca.wikipedia.org/wiki/S%C3%ADndrome_mielodispl%C3%A0stica" title="Síndrome mielodisplàstica – Catalan" lang="ca" hreflang="ca">Català</a></li><li class="interlanguage-link interwiki-da"><a href="//da.wikipedia.org/wiki/Myelodysplastisk_syndrom" title="Myelodysplastisk syndrom – Danish" lang="da" hreflang="da">Dansk</a></li><li class="interlanguage-link interwiki-de"><a href="//de.wikipedia.org/wiki/Myelodysplastisches_Syndrom" title="Myelodysplastisches Syndrom – German" lang="de" hreflang="de">Deutsch</a></li><li class="interlanguage-link interwiki-es"><a href="//es.wikipedia.org/wiki/S%C3%ADndrome_mielodispl%C3%A1sico" title="Síndrome mielodisplásico – Spanish" lang="es" hreflang="es">Español</a></li><li class="interlanguage-link interwiki-fa"><a href="//fa.wikipedia.org/wiki/%D8%B3%D9%86%D8%AF%D8%B1%D9%85_%D9%85%DB%8C%D9%84%D9%88%D8%AF%DB%8C%D8%B3%D9%BE%D9%84%D8%A7%D8%B3%D8%AA%DB%8C%DA%A9" title="سندرم میلودیسپلاستیک – Persian" lang="fa" hreflang="fa">فارسی</a></li><li class="interlanguage-link interwiki-fr"><a href="//fr.wikipedia.org/wiki/Syndrome_my%C3%A9lodysplasique" title="Syndrome myélodysplasique – French" lang="fr" hreflang="fr">Français</a></li><li class="interlanguage-link interwiki-hr"><a href="//hr.wikipedia.org/wiki/Sindrom_mijelodisplazije" title="Sindrom mijelodisplazije – Croatian" lang="hr" hreflang="hr">Hrvatski</a></li><li class="interlanguage-link interwiki-it"><a href="//it.wikipedia.org/wiki/Sindrome_mielodisplasica" title="Sindrome mielodisplasica – Italian" lang="it" hreflang="it">Italiano</a></li><li class="interlanguage-link interwiki-he"><a href="//he.wikipedia.org/wiki/%D7%94%D7%AA%D7%A1%D7%9E%D7%95%D7%A0%D7%AA_%D7%94%D7%9E%D7%99%D7%90%D7%9C%D7%95%D7%93%D7%99%D7%A1%D7%A4%D7%9C%D7%A1%D7%98%D7%99%D7%AA" title="התסמונת המיאלודיספלסטית – Hebrew" lang="he" hreflang="he">עברית</a></li><li class="interlanguage-link interwiki-lt"><a href="//lt.wikipedia.org/wiki/Mielodisplastiniai_sindromai" title="Mielodisplastiniai sindromai – Lithuanian" lang="lt" hreflang="lt">Lietuvių</a></li><li class="interlanguage-link interwiki-nl"><a href="//nl.wikipedia.org/wiki/Myelodysplasie" title="Myelodysplasie – Dutch" lang="nl" hreflang="nl">Nederlands</a></li><li class="interlanguage-link interwiki-ja"><a href="//ja.wikipedia.org/wiki/%E9%AA%A8%E9%AB%84%E7%95%B0%E5%BD%A2%E6%88%90%E7%97%87%E5%80%99%E7%BE%A4" title="骨髄異形成症候群 – Japanese" lang="ja" hreflang="ja">日本語</a></li><li class="interlanguage-link interwiki-no"><a href="//no.wikipedia.org/wiki/Myelodysplastisk_syndrom" title="Myelodysplastisk syndrom – Norwegian" lang="no" hreflang="no">Norsk bokmål</a></li><li class="interlanguage-link interwiki-pl"><a href="//pl.wikipedia.org/wiki/Zespo%C5%82y_mielodysplastyczne" title="Zespoły mielodysplastyczne – Polish" lang="pl" hreflang="pl">Polski</a></li><li class="interlanguage-link interwiki-pt"><a href="//pt.wikipedia.org/wiki/S%C3%ADndrome_mielodispl%C3%A1sica" title="Síndrome mielodisplásica – Portuguese" lang="pt" hreflang="pt">Português</a></li><li class="interlanguage-link interwiki-ru"><a href="//ru.wikipedia.org/wiki/%D0%9C%D0%B8%D0%B5%D0%BB%D0%BE%D0%B4%D0%B8%D1%81%D0%BF%D0%BB%D0%B0%D1%81%D1%82%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B9_%D1%81%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BC" title="Миелодиспластический синдром – Russian" lang="ru" hreflang="ru">Русский</a></li><li class="interlanguage-link interwiki-simple"><a href="//simple.wikipedia.org/wiki/Myelodysplastic_syndrome" title="Myelodysplastic syndrome – Simple English" lang="simple" hreflang="simple">Simple English</a></li><li class="interlanguage-link interwiki-sv"><a href="//sv.wikipedia.org/wiki/Myelodysplastiskt_syndrom" title="Myelodysplastiskt syndrom – Swedish" lang="sv" hreflang="sv">Svenska</a></li><li class="interlanguage-link interwiki-zh"><a href="//zh.wikipedia.org/wiki/%E9%AA%A8%E9%AB%93%E5%A2%9E%E7%94%9F%E5%BC%82%E5%B8%B8%E7%BB%BC%E5%90%88%E5%BE%81" title="骨髓增生异常综合征 – Chinese" lang="zh" hreflang="zh">中文</a></li><li class="uls-p-lang-dummy"><a href="#"></a></li>					</ul>
				<div class='after-portlet after-portlet-lang'><span class="wb-langlinks-edit wb-langlinks-link"><a href="//www.wikidata.org/wiki/Q954625#sitelinks-wikipedia" title="Edit interlanguage links" class="wbc-editpage">Edit links</a></span></div>			</div>
		</div>
				</div>
		</div>
		<div id="footer" role="contentinfo">
							<ul id="footer-info">
											<li id="footer-info-lastmod"> This page was last modified on 3 July 2015, at 20:56.</li>
											<li id="footer-info-copyright">Text is available under the <a rel="license" href="//en.wikipedia.org/wiki/Wikipedia:Text_of_Creative_Commons_Attribution-ShareAlike_3.0_Unported_License">Creative Commons Attribution-ShareAlike License</a><a rel="license" href="//creativecommons.org/licenses/by-sa/3.0/" style="display:none;"></a>;
additional terms may apply.  By using this site, you agree to the <a href="//wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a> and <a href="//wikimediafoundation.org/wiki/Privacy_policy">Privacy Policy</a>. Wikipedia® is a registered trademark of the <a href="//www.wikimediafoundation.org/">Wikimedia Foundation, Inc.</a>, a non-profit organization.</li>
									</ul>
							<ul id="footer-places">
											<li id="footer-places-privacy"><a href="//wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
											<li id="footer-places-about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
											<li id="footer-places-disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
											<li id="footer-places-contact"><a href="//en.wikipedia.org/wiki/Wikipedia:Contact_us">Contact Wikipedia</a></li>
											<li id="footer-places-developers"><a href="https://www.mediawiki.org/wiki/Special:MyLanguage/How_to_contribute">Developers</a></li>
											<li id="footer-places-mobileview"><a href="//en.m.wikipedia.org/w/index.php?title=Myelodysplastic_syndrome&amp;mobileaction=toggle_view_mobile" class="noprint stopMobileRedirectToggle">Mobile view</a></li>
									</ul>
										<ul id="footer-icons" class="noprint">
											<li id="footer-copyrightico">
							<a href="//wikimediafoundation.org/"><img src="/static/images/wikimedia-button.png" srcset="/static/images/wikimedia-button-1.5x.png 1.5x, /static/images/wikimedia-button-2x.png 2x" width="88" height="31" alt="Wikimedia Foundation"/></a>						</li>
											<li id="footer-poweredbyico">
							<a href="//www.mediawiki.org/"><img src="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="//en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_132x47.png 1.5x, //en.wikipedia.org/static/1.26wmf13/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" /></a>						</li>
									</ul>
						<div style="clear:both"></div>
		</div>
		<script>if(window.jQuery)jQuery.ready();</script><script>if(window.mw){
mw.loader.state({"ext.globalCssJs.site":"ready","ext.globalCssJs.user":"ready","site":"loading","user":"ready","user.groups":"ready"});
}</script>
<link rel="stylesheet" href="//en.wikipedia.org/w/load.php?debug=false&amp;lang=en&amp;modules=ext.cite.styles%7Cext.gadget.DRN-wizard%2CReferenceTooltips%2CWatchlistGreenIndicators%2Ccharinsert%2Cfeatured-articles-links%2CrefToolbar%2Cswitcher%2Cteahouse%7Cext.wikimediaBadges&amp;only=styles&amp;skin=vector&amp;*" />
<script>if(window.mw){
mw.loader.load(["ext.cite.a11y","mediawiki.toc","mediawiki.action.view.postEdit","mediawiki.user","mediawiki.hidpi","mediawiki.page.ready","mediawiki.searchSuggest","ext.cirrusSearch.loggingSchema","mmv.bootstrap.autostart","ext.imageMetrics.loader","ext.eventLogging.subscriber","ext.wikimediaEvents","ext.wikimediaEvents.statsd","ext.navigationTiming","ext.gadget.teahouse","ext.gadget.ReferenceTooltips","ext.gadget.WatchlistGreenIndicators","ext.gadget.DRN-wizard","ext.gadget.charinsert","ext.gadget.refToolbar","ext.gadget.switcher","ext.gadget.featured-articles-links","ext.visualEditor.targetLoader","schema.UniversalLanguageSelector","ext.uls.eventlogger","ext.uls.interlanguage"],null,true);
}</script>
<script>if(window.mw){
document.write("\u003Cscript src=\"//en.wikipedia.org/w/load.php?debug=false\u0026amp;lang=en\u0026amp;modules=site\u0026amp;only=scripts\u0026amp;skin=vector\u0026amp;*\"\u003E\u003C/script\u003E");
}</script>
<script>if(window.mw){
mw.config.set({"wgBackendResponseTime":79,"wgHostname":"mw1254"});
}</script>
	</body>
</html>
